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Aarti R. Chawla 
CAMKII REGULATION OF ASTROCYTIC GLUTAMATE UPTAKE 
 
Glutamate clearance by astrocytes is an essential part of physiological excitatory 
neurotransmission. Failure to adapt or maintain low levels of glutamate in the central 
nervous system is associated with multiple acute and chronic neurodegenerative diseases. 
The primary excitatory amino acid transporters (EAATs) in human astrocytes are EAAT1 
and EAAT2 (GLAST and GLT-1 respectively in rodents). While the inhibition of a 
ubiquitously-expressed serine/threonine protein kinase, the calcium/calmodulin-
dependent kinase (CaMKII) results in diminished glutamate uptake in cultured primary 
rodent astrocytes, the molecular mechanism underlying this regulation is unknown. In 
order to delineate this mechanism, we use a heterologous expression model to explore 
CaMKII regulation of EAAT1 and EAAT2. In transiently transfected HEK293T cells, 
pharmacological inhibition of CaMKII and overexpression of a dominant-negative 
version of CaMKII (Asp136Asn) reduces [3H]-glutamate uptake by EAAT1, without 
altering EAAT2 mediated glutamate uptake. Surprisingly, overexpression of a 
constitutively active autophosphorylation mutant (Thr287Asp) to increase autonomous 
CaMKII activity and a mutant incapable of autophosphorylation (Thr287Val) had no 
effect on either EAAT1 or EAAT2 mediated glutamate uptake. Pulldown of FLAG-
tagged glutamate transporters suggests CaMKII does not interact with EAAT1 or 
EAAT2. SPOTS peptide arrays and recombinant GST-fusion proteins of the intracellular 
N- and C-termini of EAAT1 identified two potential phosphorylation sites at residues 
Thr26 and Thr37 in the N-terminus. Introducing an Ala (a non-phospho mimetic) but not 
	 viii 
an Asp (phosphomimetic) at Thr37 diminished EAAT1-mediated glutamate uptake, 
suggesting that the phosphorylation state of this residue is important for constitutive 
EAAT1 function. In sum, this is the first report of a glutamate transporter being identified 
as a direct CaMKII substrate. These findings indicate that CaMKII signaling is a critical 
driver of homeostatic glutamate uptake by EAAT1. Aberrations in basal CaMKII activity 
disrupt glutamate uptake, which can perpetuate glutamate-mediated excitotoxicity and 
result in cellular death.	
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INTRODUCTION 
The non-essential amino acid, L-glutamate, is the primary excitatory 
neurotransmitter in the mammalian central nervous system (CNS). It is essential for 
physiological processes such as early brain development, synaptic plasticity during 
learning and memory, and cognition. However, glutamate also functions as a neurotoxin 
when synaptic levels are not tightly controlled. A pathological state known as glutamate-
induced excitotoxicity ensues, wherein excessive activation of glutamatergic receptors 
ultimately results in neuronal dysfunction and death. Neurodegenerative states such as 
ischemia, Alzheimer’s and amyotrophic lateral sclerosis are closely associated with 
glutamate-induced excitotoxicity (Rothstein, Martin et al. 1992, Rao, Baskaya et al. 1998, 
Cassano, Serviddio et al. 2012). Collectively, these disease states account for a 
tremendous emotional and financial burden on patients, family, health care providers, and 
the government. It is essential to better our understanding of the common mechanisms 
underlying these diseases states in order to eventually devise successful therapeutics.  
A family of sodium-dependent excitatory amino acid transporters (EAATs) is 
responsible for glutamate clearance during neurotransmission. Astrocytes express 
EAAT1 and EAAT2, proteins considered to be the molecular mainstays of glutamate 
uptake. Interestingly, alterations in a calcium-regulated multifunctional serine/threonine 
protein kinase, the calcium/calmodulin-dependent (CaMKII), have been shown to disrupt 
glutamate uptake via the astrocytic glutamate transporters (Ashpole, Chawla et al. 2013). 
CaMKII is rapidly activated as a result of glutamate-induced excitotoxic calcium 
signaling, followed by subsequent aggregation and inactivation (Aronowski, Grotta et al. 
1992). In fact, CaMKII inactivation leading to a loss of CaMKII signaling has been 
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shown to directly correlate with the extent of neuronal damage, a hallmark feature of 
neurodegenerative diseases. Not surprisingly, astrocytic EAAT dysregulation and altered 
intracellular calcium signaling have both been demonstrated in neurodegeneration. In 
keeping with these findings, the question arises: what is the mechanism of CaMKII 
regulation of the astrocytic glutamate transporters? 
The background of this dissertation will focus on the mechanisms involved in 
glutamatergic neurotransmission, and the structure, function, and regulation of both 
glutamate transporters and CaMKII. By providing insight into these mechanisms, I hope 
to provide a rationale underlying the biological importance of CaMKII regulation of 
EAATs. 
 
Glutamatergic neurotransmission  
The earliest studies examining the role of the acidic amino acid L-glutamate were 
related to its involvement in the Krebs cycle (Krebs 1935, Krebs 1935) and the 
detoxification of ammonia (Weil-Malherbe 1950, Weil-Malherbe 1950), suggesting a 
crucial metabolic role for this molecule. In fact, studies demonstrating that glutamate 
served as a precursor for gamma-aminobutyric acid (GABA), the key inhibitory 
neurotransmitter in the brain (Roberts and Frankel 1950), pre-dated reports suggesting its 
involvement in direct chemical signaling in the brain. It is perhaps not surprising that 
glutamate’s role as a key excitatory neurotransmitter itself temporally surface after these 
findings; a non-essential amino acid such as glutamate is an atypical choice for a key 
neurotransmitter.  
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In 1959 Curtis et al. (Curtis, Phillis et al. 1959) demonstrated that L-glutamate 
caused depolarization and excitation in feline spinal neurons, providing one of the first 
reports implicating glutamate as a neurotransmitter. Since these studies, glutamate has 
been shown to be an important player in numerous aspects of normal brain function 
including cognition, fast synaptic transmission, and synaptic plasticity during learning 
and memory (for reviews see (Fonnum 1984, Danbolt 2001, Mayer and Armstrong 
2004)). Furthermore, the role of glutamate as the primary excitatory amino acid 
neurotransmitter in the mammalian central nervous system has been firmly established 
(Karlsen and Fonnum 1978, Fonnum, Soreide et al. 1981, Fonnum, Storm-Mathisen et al. 
1981). Interestingly, prior to Curtis’ work in the late 1950s, Newhouse and Lucas 
demonstrated neurotoxicity associated with injecting glutamate into the immature murine 
retina, thus highlighting a second role of L-glutamate- one of a neurotoxin (Lucas and 
Newhouse 1957, Lucas, Newhouse et al. 1957). For the next few decades, numerous 
studies were performed in parallel that confirmed glutamate’s role as both a key 
neurotransmitter and a neurotoxin. To date, however, scientists still strive to establish a 
better understanding of how fine alterations in the concentration of glutamate in the brain 
switch its function from that of a neurotransmitter to a neurotoxin. 
During physiological chemical synaptic transmission, the arrival of an action 
potential at the pre-synaptic nerve terminal results in cellular depolarization (Hodgkin 
and Huxley 1952, Hodgkin, Huxley et al. 1952). One of the consequences of the 
membrane potential becoming more positive as a result of depolarization is calcium 
influx through voltage gated calcium channels. Glutamate, packaged in synaptic vesicles, 
is released via a calcium-dependent process from the pre-synaptic neuron into the 
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synaptic cleft (Katz and Miledi 1968, Katz and Miledi 1968, Haydon and Carmignoto 
2006). ‘Resting’ glutamate concentrations in the extracellular fluid and cerebrospinal 
fluid have been estimated to range between 3-10µM (Hamberger and Nystrom 1984), 
which is estimated to comprise a very small percentage of total glutamate in the entire 
brain which ranges from 5-15mmol per kg wet weight (Choi 1990). However, following 
pre-synaptic vesicular release the concentration of synaptic glutamate rises rapidly to 
~3mM (Diamond and Jahr 1997). Synaptic glutamate binds to and activates glutamate 
receptors located on the membranes of the pre-synaptic neuron, post-synaptic neuron and 
glial cells to mediate depolarization and activate intracellular signaling pathways, 
although the receptors located on post-synaptic neurons are thought to be the most 
important for synaptic neurotransmission. Post-synaptic glutamate receptors are of two 
different types: ionotropic and metabotropic. Glutamate receptors require low micromolar 
(1-10µM) concentrations of glutamate to induce activation (Choi 1987). In brief, 
glutamate activates both ionotropic and metabotropic receptors, resulting in 
depolarization due to cationic influx and the activation of second messenger systems. 
Synaptic glutamate concentrations during neurotransmission ensure efficient excitatory 
neurotransmission by maintaining the synaptic concentration below those required for 
tonic activation of the glutamate receptors, while providing enough extracellular 
glutamate to saturate the receptors (Shen and Meyer 1999, Danbolt 2001, Ferraguti and 
Shigemoto 2006).  
Ionotropic receptors are of three kinds, named so on the basis of their respective 
exogenous, subtype-selective pharmacological ligands: N-methyl-D-aspartate (NMDA), 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainate receptors. 
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Also referred to as ligand-gated ion channels, ionotropic receptors are permeable, with 
varying degrees of selectivity, to Na+, Ca2+ and K+ ions (for reviews see (Hollmann and 
Heinemann 1994, Wollmuth and Sobolevsky 2004)). In particular, NMDA receptors 
(NMDARs) have a higher affinity for glutamate than either AMPA or kainate receptors 
(Hollmann and Heinemann 1994). NMDARs require binding of glutamate as well as 
simultaneous cellular depolarization to occur in order to relieve the Mg2+ block to allow 
ionic flux to occur through the receptor. Once activated by glutamate, ionotropic 
receptors allow for the entry of both Na+ and Ca2+ ions. The NMDAR is considered the 
molecular mainstay in controlling synaptic plasticity and memory function in the brain 
(Collingridge, Kehl et al. 1983, Herron, Lester et al. 1986). Generally, NMDARs have 
been implicated in the late or slower phase of the excitatory post-synaptic potential 
(EPSP) time course, while it is thought that non-NMDAR ionotropic receptors control the 
amplitude and early phase of the EPSP time course. Ionotropic receptors mediate and 
process information in the brain that can account for alterations in synaptic efficiency 
involved in physiological and pathological processes such as learning and memory, 
development, the maintenance of cellular connections and pain perception (Bliss and 
Collingridge 1993, Woolf and Salter 2000).  
The activity of metabotropic receptors (mGluRs), on the other hand, is associated 
with heterotrimeric guanine nucleotide binding proteins (G proteins). Signaling 
mechanisms for mGluRs, based on the G-proteins they couple to, involve 
phosphoinositide-dependent processes, protein kinase C or cyclic AMP, which can be 
either inhibitory or excitatory (Ferraguti and Shigemoto 2006, Niswender and Conn 
2010). mGluRs can be found on both neurons and glial cells, based on the receptor or 
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splice variants in question, and are typically associated with slow synaptic function and 
neuronal excitability. This type of glutamate receptor is thought to be necessary for 
synaptic development and plasticity, as well as motor control, autonomic function, 
cognition and the receipt of sensory information. Classically, there are three families of 
mGluRs: group I mGluRs, which couple to Gq /G11 and lead to activation of PKC and the 
mobilization of calcium, and group II and III mGluRs, which couple to Gi/o proteins and 
are thought to inhibit adenylyl cyclase. However, numerous other signaling mechanisms 
are also thought to couple to the activity of the mGluRs (Niswender and Conn 2010).   
Excessive stimulation of ionotropic receptors is associated with a condition 
termed glutamate-induced excitotoxicity, ultimately resulting in neuronal death (Olney 
and Sharpe 1969, Choi 1992, Rothman and Olney 1995). Early studies suggested that cell 
death associated with glutamate-induced excitotoxicity was of a necrotic nature, based on 
acidophilic neurons and mitochondrial flocculent densities observed in electron 
microscopic images (Olney 1969, Olney 1971, Ingvar, Morgan et al. 1988). However, the 
observation of a calcium-dependent delayed neuronal cell death following exposure to 
glutamate (Choi 1987, Randall and Thayer 1992) spurred interest on the nature of 
glutamate-induced cell death. Studies now provide compelling evidence that apoptotic 
phenotypes such as intranucleosomal DNA cleavage and the involvement of caspases are 
a result of neuronal glutamate exposure (Kure, Tominaga et al. 1991, Ankarcrona, 
Dypbukt et al. 1995, Choi 1996). Thus, cell death elicited by glutamate is now attributed 
to both apoptosis and necrosis.  
NMDAR receptor activation leads to an increase in the ion fluxes of Na+, Ca2+ 
and K+ ions while ion influx through the AMPA receptor is dependent on the subunit 
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composition of the receptor, namely the presence of the GluR2 subunit which makes it 
impermeable to calcium (Choi 1987, Liu and Zukin 2007). Ca2+ activation and overload 
(Coultrap, Vest et al. 2011), and Na+ influx through these glutamate receptors cannot be 
overlooked as they lead to aberrant activation of voltage-gated ion channels such as the 
L-type calcium channel. Prolonged neuronal depolarization, ionic imbalances and ATP 
depletion are secondary effects associated with glutamate-induced excitotoxicity (Yi and 
Hazell 2006). Possibly the most pertinent protein to the pathological state of 
excitotoxicity is the NMDAR, highly permeable to calcium ions and often referred to as 
the ‘death receptor’ since overstimulation leads to phenotypes of calcium overload, 
aberrant cellular signaling and neuronal death associated with excitotoxicity (Tu, Xu et 
al. 2010, Coultrap and Bayer 2012). The contribution of mGluRs to the process of 
excitotoxicity remains ambiguous, although the activation of Group I mGluRs has been 
described to contribute to neuronal cell death (Hilton, Nunez et al. 2006). Taken together, 
it is evident that a system must exist to effectively clear excess extracellular glutamate in 
order to prevent aberrant signaling and subsequent neuronal damage and ultimately, 
death.  
 
Glutamate metabolism in the CNS 
Glutamate is unable to enter the brain by crossing the blood brain barrier (BBB), 
which comprises of capillary endothelial cells lining cerebral microvasculature and 
astrocyte end-feet processes, perivascular neurons and pericytes that insulate the brain 
from plasma (Hawkins, O'Kane et al. 2006, Hawkins 2009). However, glutamate is 
capable of exiting the BBB via EAAT1-3 that are present on the abluminal (facing the 
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brain) membrane of the BBB (Hutchison, Eisenberg et al. 1985, O'Kane, Martinez-Lopez 
et al. 1999). Thus, in the brain, the neurotransmitter glutamate needs to be synthesized. 
This process can occur in a few different ways: 1) de novo synthesis from glucose 2) the 
glutamate-glutamine cycle and 3) neuronal synthesis from astrocytic lactate (reviewed in 
(Danbolt 2001, Krzyzanowska, Pomierny et al. 2014)).  Briefly, the different mechanisms 
that are involved in glutamate synthesis are discussed below. 
 
De novo synthesis of glutamate from glucose  
The mammalian brain is the highest consumer of glucose in comparison to other 
tissues in the body, and utilizes this substrate as its primary source of energy (Erbsloh, 
Bernsmeier et al. 1958). Glucose can easily traverse the BBB via the GLUT1 transporter 
present on endothelial cells (Mueckler, Caruso et al. 1985, Hemmila and Drewes 1993), 
making it a readily available substrate for the de novo synthesis of glutamate. In fact, it is 
estimated that almost all the glucose that enters the brain is eventually converted to 
glutamate (Shen, Petersen et al. 1999). Once glucose enters an astrocyte via astrocytic 
end feet that are tightly coupled to the neurovascular unit and gap junctions, it is broken 
down into pyruvic acid via glycolysis and eventually converted to glutamate through the 
intermediate by-product of α-ketoglutarate via the tricarboxylic acid (TCA) cycle. 
It is noteworthy that a nonessential amino acid such as glutamate serves as what is 
considered the key excitatory neurotransmitter in the brain. Firstly, glutamate is present 
in the brain at a higher concentration that any other amino acid, thus making it readily 
available to use for the process of neurotransmission. Secondly, glucose is ubiquitous in 
the mammalian diet, making the key substrate for glutamate synthesis one that is easily 
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available. Lastly, glucose can easily enter the brain where it serves a number of other 
functions, thus making the cost of glucose uptake into the brain energetically favorable.  
 
The glutamate-glutamine cycle 
Once glutamate is taken up from the extracellular fluid by glia, it is converted into 
glutamine by glutamine synthetase, an enzyme detected only in glia (Martinez-
Hernandez, Bell et al. 1977), via an ATP-dependent process (commonly known as the 
glutamate-glutamine cycle). It is then shuttled back into neurons through the astrocytic 
system N transporter 1 (Chaudhry, Reimer et al. 1999) and neuronal system A transporter 
(Varoqui, Zhu et al. 2000). Glutamine is then converted back to glutamate through 
phosphate-activated glutaminase (Laake, Takumi et al. 1999).  
 
Neuronal synthesis of glutamate from astrocytic lactate 
Alternately, glutamate taken up by glia is converted into α-ketoglutarate which is 
metabolized through the tricarboxylic acid (TCA) cycle into a number of different 
substrates. One fate of α-ketoglutarate is its conversion to lactate, which is then shuttled 
back to neurons through monocarboxylate transporters and converted to glutamate 
(Halestrap and Price 1999).  
 
Regardless of what the source of the substrate that eventually results in neuronal 
glutamate is, once it is synthesized it is packaged into synaptic vesicles by vesicular 
glutamate transporters, and is ready to be exocytosed. It is this vesicular glutamate that is 
released by the presynaptic neuron during glutamatergic neurotransmission.  
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Glutamate clearance 
The levels of extracellular glutamate must be tightly controlled to ensure efficient 
excitatory neurotransmission and to prevent aberrant receptor activation and subsequent 
excitotoxicity (Choi 1987, Choi 1992, Nieoullon, Canolle et al. 2006). In fact, it is 
thought that >99% of glutamate resides intracellularly in the brain (Danbolt 2001). Thus, 
a critical element of glutamatergic signaling is the clearance of excess synaptic 
glutamate. To date, there has been no evidence of an extracellular method of 
metabolizing glutamate (Danbolt 2001, Sheldon and Robinson 2007). Synaptosomal 
preparations measuring uptake of radiolabeled glutamate have suggested the contribution 
of sodium-independent transport as only a small percentage of total glutamate clearance 
(<5%) (Robinson 1998). Low-affinity glutamate transporters have been described, 
however they are poorly-characterized, appear to serve a redundant function as the high-
affinity glutamate transporters mentioned below, and their existence as a separately entity 
is controversial (reviewed in (Danbolt 2001)). Instead, it appears that a family of sodium 
dependent, high affinity transporters, known as excitatory amino acid transporters 
(EAATs), are instrumental in removing the majority of glutamate from the synaptic cleft 
(Diamond and Jahr 1997, Amara and Fontana 2002, Sheldon and Robinson 2007). A 
schematic of glutamatergic neurotransmission encompassing the proteins and molecules 
described thus far is shown in Figure 1. 
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Figure 1: Schematic of an excitatory synapse in the central nervous system. Excitatory 
neurotransmitter glutamate is released in packaged vesicles from pre-synaptic nerve 
terminals, and activates both ionotropic and metabotropic receptors on neurons and 
astrocytes. The clearance of excess extracellular glutamate is mediated by the excitatory 
amino acid transporters, a family of sodium-dependent glutamate transporters. Glutamate 
synthetase in glial cells converts glutamate into glutamine (Gln, not shown), following 
which it is shuttled back into neurons via the System N and System A transporters. 
Additionally, the system Xc- transport system accounts for a small percentage of glutamate 
transport back into neurons. 
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Figure 2: Sequence alignment of the five members of the canonical human 
excitatory amino acid transporter family (hEAAT1-5). * indicates sequence 
identity while : indicates conversation. The colors associated with this analysis are: 
red=small (includes aromatics and hydrophobics, AVFPMILW), blue= acidic (DE), 
magenta (basic, RK), green (hydroxyl, sulfhydryl, amine, and glycine, STYHCNGQ), 
and gray=unusual amino/imino acids. The N-terminus domain has been underlined in 
black and the C-terminus domain in gray below the aligned sequences. 
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EAAT structure and function 
EAATs belong to the Solute Carrier (SLC1) gene family of transporters, a diverse 
group of membrane transport proteins. GLAST (Storck, Schulte et al. 1992), GLT-1 
(Pines, Danbolt et al. 1992), EAAC1 (Kanai and Hediger 1992), EAAT4 (Fairman, 
Vandenberg et al. 1995), and EAAT5 (Arriza, Eliasof et al. 1997) were identified through 
the 1990s, and have since been reported to share 50-60% sequence homology (Figure 2). 
The human homologs for GLAST, GLT-1 and EAAC1 are named EAAT1, EAAT2 and 
EAAT3 respectively (reviewed in (Danbolt 2001). Structurally, glutamate transporters 
have been suggested to exist as homomeric trimers, with eight transmembrane domains 
based on cysteine scanning mutagenesis of GLT-1 and comparison to the bacterial 
glutamate transporter homolog crystallized from Pyrococcus horikoshii (Yernool, 
Boudker et al. 2004, Peacey, Miller et al. 2009). 
Uptake by the EAATs relies on the driving force of the thermodynamically 
favorable Na+ electrochemical gradient: 1 glutamate-, 3 Na+ molecules and 1 H+ are taken 
up by the cell, while a K+ ion is counter-transported (Figure 2) (reviewed in (Danbolt 
2001, Amara and Fontana 2002)). Initiation of this process is thought to involve the 
recruitment of 1 glutamate-, 3 Na+ molecules and 1 H+ from the extracellular space, while 
the transporter is hypothesized to be in an outward-facing conformation. Once these 
substrates bind to the surface of the transporter, a conformational change occurs and the 
EAATs face inward, releasing these substrates into the intracellular space. At this point, a 
K+ ion is recruited to the transporter surface, after which the conformation switches to 
one that is outward-facing again and the bound ion is released extracellularly (reviewed 
	 14 
in (Billups, Rossi et al. 1998, Robinson 1998)). In addition to these ionic fluxes, currents 
elicited by EAAT4 and EAAT5 comprise of an inward Cl- flux.  
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Figure 3: Ionic flux involved in glutamate uptake via the glutamate 
transporters EAAT1-5. 3 Na+ molecules, 1 H+, and 1 Glu- ion are taken up 
by an astrocyte as a result of the thermodynamically favorable Na+ gradient, 
while a K+ ion is counter-ported into the extracellular space. In the cases of 
EAAT4 and EAAT5, a Cl- is also transported into the cell (not shown). 
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EAAT expression  
GLAST/EAAT1 and GLT-1/EAAT2 predominantly localize to astrocytes and to a 
lesser extent on other glial cells and neurons (Rothstein, Dykes-Hoberg et al. 1996, 
Danbolt 2001), whereas EAAC1, EAAT4 and EAAT5 are considered neuronal (Amara 
and Fontana 2002). GLAST/EAAT1 and GLT-1/EAAT2 will be described in greater 
detail in the next section, while I will focus on the neuronal transporters for the next few 
paragraphs. Transporter localization and nomenclature is summarized in Table 1. 
EAAC1/EAAT3 is the primary neuronal glutamate transporter. Its expression has 
been described in pyramidal cells in both the cortex and hippocampus, as well as in 
GABAergic neurons, oligodendrocytes and even in astrocytes at very low levels 
(Rothstein, Martin et al. 1994, Domercq, Sanchez-Gomez et al. 1999, Kugler and Schmitt 
1999). Outside of the central nervous system, EAAC1 expression is observed in the 
kidney and small intestine. EAAC1 is highly expressed early in development and thought 
to account for the majority of glutamate clearance before GLT-1 expression increases 
(reviewed in (Sims and Robinson 1999)). Knockdown of EAAC1 with antisense 
oligonucleotides resulted in a seizure phenotype but did not elevate striatal extracellular 
glutamate and produced only a mild excitotoxic phenotype (Rothstein, Dykes-Hoberg et 
al. 1996). The first EAAC1 knockout mouse model did not exhibit any overt neurological 
phenotype (Peghini, Janzen et al. 1997), however progressive age-dependent 
neurodegeneration associated with decreased glutathione levels in the brain was 
described in a more recent EAAC1 knockout mouse (Aoyama, Suh et al. 2006).  
EAAT4 is selectively expressed on GABAergic Purkinje neurons in the 
cerebellum with much lower expression in the forebrain (Furuta, Rothstein et al. 1997), 
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and has been shown to transport glutamate with a slower turnover (Mim, Balani et al. 
2005). EAAT4 expression appears to be concentrated adjacent to excitatory synapses, 
close to glial cell contacts. EAAT3 and EAAT4 are located peri-synaptically and/or in 
spines (reviewed in (Danbolt 2001)). It has been hypothesized, based on their location, 
that EAAT3 and EAAT4 are positioned to regulate the amount of glutamate escaping the 
synapse. 
EAAT5 is located on presynaptic neurons in rod photoreceptors retinal bipolar 
cells (Arriza, Eliasof et al. 1997). A major feature of EAAT5 is its ability to conduct Cl- 
ions gated by the binding of Na+ and Glutamate-, but thermodynamically uncoupled to 
Glutamate- flux (Wersinger, Schwab et al. 2006). This conductance, in turn, causes 
hyperpolarization of the presynaptic nerve terminal. EAAT5 has thus been hypothesized 
to play a larger role in transmitter release rather than glutamate clearance in the retina 
(Veruki, Morkve et al. 2006). As GLAST/EAAT1 and GLT-1/EAAT2 are the 
predominant glutamate transporters on astrocytes, I focus on these two transporters for 
the remainder of my work.   
 
Astrocytic EAAT transporters  
The glial glutamate transporters, GLAST/EAAT1 and GLT-1/EAAT2 are 
considered to be the primary molecular mainstays of glutamate clearance at the synaptic 
cleft. This idea is supported by a number of reasons. Firstly, astrocytic sodium-dependent 
glutamate transporters are present in extremely high densities in certain regions of the 
brain. Specifically, astrocytes in the hippocampal CA1 stratum radiatum and the 
cerebellar molecular layer have been reported to contain 15000 and 21000 glial glutamate 
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transporter molecules respectively per µm3 tissue as compared to 2000 neuronal 
transporter (EAAT4, specifically) molecules (Dehnes, Chaudhry et al. 1998, Lehre and 
Danbolt 1998). Secondly, utilizing chronic antisense oligonucleotides to inhibit glutamate 
transporter synthesis (either GLAST or GLT-1) resulted in neurodegenerative excitotoxic 
characteristics, elevated extracellular glutamate levels, and progressive paralysis in vivo 
(Rothstein, Dykes-Hoberg et al. 1996). Mouse knockout models further substantiate these 
findings. A GLAST knockout mouse exhibits cerebellar ataxia, mild to moderate 
neuronal death as a result of an excitotoxic insult and inability to perform challenging 
tests involving coordination (Watase, Hashimoto et al. 1998). In an independent study, 
GLAST mice were also described to be more susceptible to seizures (Ueda, Doi et al. 
2002). A homozygous GLT-1 knockout mouse exhibited severe neuronal death as a result 
of a cortical ischemic insult and had a higher incidence of developing lethal spontaneous 
epileptic seizures (Tanaka, Watase et al. 1997). Knockout models of neuronal glutamate 
transporters did not produce overt neurological phenotypes.  
High levels of GLAST expression have been reported in the retina and 
cerebellum. GLAST deficiency has a much greater impact on retinal damage following 
ischemia in mice compared to depleting GLT-1, thus underscoring the importance of 
targeting glutamate uptake through GLAST during conditions of blindness and 
degeneration as a result of ischemic retinal disease (Harada, Harada et al. 1998). GLAST 
is also localized to Bergmann glia, accounting for the majority of cerebellar glutamate 
uptake (Rothstein, Martin et al. 1994, Rothstein, Dykes-Hoberg et al. 1996). A GLAST 
knockout mouse exhibits cerebellar ataxia and deficits in coordination whereas a GLT-1 
knockout mouse does not have any cerebellar effects. Lastly, a study utilizing chronic 
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antisense oligonucleotides against GLAST and GLT-1 individually demonstrated 
comparable levels of neuronal injury between the two knockdowns as a result of an 
ischemia insult, and elevated extracellular glutamate. 
GLT-1 is highly expressed throughout the neuroaxis, but is particularly prevalent 
in cortical and hippocampal astrocytes (Rothstein, Martin et al. 1994, Lehre, Levy et al. 
1995, Lehre and Danbolt 1998). Its expression has been described in developing neurons, 
cultured neurons and oligodendrocytes (Rothstein, Martin et al. 1994, Domercq, Sanchez-
Gomez et al. 1999) Electron microscopy studies have identified GLT-1 expression on 
astrocytic processes ensheathing the synapse (Lehre, Levy et al. 1995). Although GLT-
1/EAAT2 has been reported to account for more than 90% of total glutamate transport 
activity in the forebrain, studies involving knockdown of GLAST and GLT-1 
demonstrate a comparable neurotoxic phenotype, suggesting the importance of both these 
transporters in maintaining tight control of extracellular glutamate levels in the brain 
(Rothstein, Dykes-Hoberg et al. 1996).  
Given these data, much of the literature on glutamate transporter activity has 
focused on GLT-1/EAAT2 activity. However, it is now evident that based on the region 
of the brain and cell type being studied, GLT-1 and GLAST expression differs and 
consequently account for different percentages of glutamate uptake based on these varied 
expression patterns. Both GLAST and GLT-1 have been shown to be crucial for 
astrocytic glutamate uptake, supported by both knockout models and antisense 
oligonucleotide studies described previously. In the next few sections, I will address 
mechanisms of both acute and chronic regulation of these transporters, providing 
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examples substantiating how alterations in both transporters result in functional changes 
in the brain. 
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Human 
transporter 
nomenclature 
Rodent 
homolog 
nomenclature 
Gene 
name 
Cellular localization Tissue 
localization 
References 
EAAT1 GLAST SLC1A3 Astrocytes, 
oligodendrocytes 
Highest in 
retina and 
cerebellum, 
also expressed 
in cortex, 
hippocampus, 
and basal 
ganglia 
(Rothstein, 
Dykes-Hoberg 
et al. 1996), 
(Danbolt 
2001) 
EAAT2 GLT-1 SLC1A2 Astrocytes, 
oligodendrocytes, 
neurons 
Ubiquitously 
expressed in 
the CNS 
(Rothstein, 
Dykes-Hoberg 
et al. 1996), 
(Danbolt 
2001) 
EAAT3 EAAC1 SLC1A1 Neurons (pyramidal 
cortical neurons, both 
glutamatergic and 
GABAergic), 
oligodendrocytes, 
astrocytes at very low 
levels 
Hippocampus, 
cortex 
(Rothstein, 
Martin et al. 
1994, 
Domercq, 
Sanchez-
Gomez et al. 
1999, Kugler 
and Schmitt 
1999) 
EAAT4 EAAT4 SLC1A6 Neurons (primarily 
GABAergic Purkinje 
cells), astrocytes 
Cerebellum (Fairman, 
Vandenberg et 
al. 1995, 
Furuta, 
Rothstein et al. 
1997) 
EAAT5 EAAT5 SLC1A7 Neurons (rod 
photoreceptors and 
bipolar cells) 
Retina (Arriza, 
Eliasof et al. 
1997) 
 
 
 
  
Table 1: EAAT localization. Representation of the human and rodent 
nomenclature for the glutamate transporters, associated gene name, and cellular 
and tissue localization. 
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Regulation of EAATs  
Regulation of the EAATs has been shown to occur at virtually any step of gene 
expression, from transcription, to translation, as well as post-translational modifications 
of the transporter protein. This section focuses on the regulation of the astrocytic 
transporters GLAST/EAAT1 and EAAT2/GLT1. Based on prior work, chronic versus 
acute alterations in transporter activity have been attributed to different mechanisms. 
Chronic or long-term changes in transporter activity are thought to be dependent on 
transcription or translation, assembly of the multimeric structure, partial glycosylation in 
the endoplasmic reticulum followed by terminal glycosylation, and insertion in the 
plasma membrane. In total, these changes occur as a result of de novo synthesis and a 
change in the total number of transporters (reviewed in (Robinson 2006, Fontana 2015)). 
For example, the most extensively studied of the glutamate transporters EAAC1/EAAT3, 
has a degradation half-life in the order of a few hours (Yang and Kilberg 2002). 
Conversely, rapid alterations in transporter activity that occur within minutes are 
typically thought to occur independently of these mechanisms. Rapid changes are thought 
to occur as a result of re-distribution of transporters to the plasma membrane, without 
changing the total number of cellular transporters available (reviewed in (Robinson 2002, 
Robinson 2006)). We will first discuss chronic mechanisms/examples followed by acute 
mechanisms/examples underlying alterations in glutamate transporter activity.   
 
Transcription 
Transcription is a key mechanism implicated in the chronic regulation of 
glutamate transporters. Although this dissertation focuses on acute regulatory 
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mechanisms of glutamate uptake, a brief discussion on a ‘long-term’ mechanism such as 
transcription may help us establish a temporal association between extracellular events 
and cellular regulatory mechanisms governing glutamate uptake.  
 
Glutamate-induced alterations in the regulation of GLAST/EAAT1 and related genes 
Although it was known that neurotransmitters resulted in the activation of 
transmitter receptors on astrocytes (Bowman and Kimelberg 1984), it took another 
decade for scientists to report that the neurotransmitter glutamate was instrumental in 
mobilizing calcium in astrocytes via ionotropic and metabotropic receptors on these cells 
(Cornell-Bell, Finkbeiner et al. 1990, Nedergaard 1994). As the glutamate transporters 
were cloned within that time frame, subsequent studies began to shed light on the 
relationship between the neurotransmitter and ligand for the glutamate transporters, 
glutamate, and cellular signaling pathways in astrocytes.  
The application of glutamate decreased GLAST mRNA expression in cerebellar 
chicken Bergmann glia cells, leading to compromised glutamate uptake (Lopez-Bayghen, 
Espinoza-Rojo et al. 2003, Rosas, Vargas et al. 2007). Transcriptional regulation of 
GLAST/EAAT1 resulting in alterations in GLAST/EAAT1 expression and activity 
occurs through both calcium-dependent and independent mechanisms. Calcium influx 
through the AMPA and kainate receptors, the activation of the kinase PKC, and the 
availability of the transcription factor C-Jun were implicated as key players in the 
glutamate-mediated decrease in GLAST transcriptional regulation (Gonzalez and Ortega 
1997, Lopez-Bayghen, Espinoza-Rojo et al. 2003, Lopez-Bayghen and Ortega 2004). The 
GLAST/EAAT1 promoter has been shown to contain a canonical sequence for the PKC-
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inducible activator protein (AP-1) transcription factor (Espinoza-Rojo, Lopez-Bayghen et 
al. 2000). Application of glutamate and the glutamate analogue, D-aspartate (D-Asp) 
increases AP-1 binding directly to the GLAST/EAAT1 promoter thus decreasing its 
expression (Ramirez-Sotelo, Lopez-Bayghen et al. 2007, Martinez-Lozada, Hernandez-
Kelly et al. 2011, Maria Lopez-Colome, Martinez-Lozada et al. 2012). Furthermore, D-
Asp induced calcium influx and phosphorylation of the mammalian target of rapamycin 
(mTOR) in a PI3K/PKB/Akt-dependent manner in Müller radial glia, leading to increased 
AP-1 DNA binding (Maria Lopez-Colome, Martinez-Lozada et al. 2012). In fact, calcium 
influx in Bergmann glia cells has also been shown to activate CaMKII and downstream 
tyrosine kinases such as PI3K and MAPK, transiently phosphorylate the TF CREB 
(cAMP response-element binding protein) driving c-fos expression (Aguirre, Lopez-
Bayghen et al. 2002, Lopez-Bayghen, Aguirre et al. 2003). CaMKII in particular, has 
been shown to regulate the activity of both AP-1 and C-Jun, transcription factors 
implicated in the regulation of GLAST/EAAT1 promoter activity (Mishra, Mishra et al. 
2005). Although this finding was in human monocyte cells, we can extrapolate that the 
transcriptional regulation exerted by CaMKII may occur in a similar manner in 
astrocytes.   
The EAAT1 promoter is thought to contain multiple consensus sites for Yin Yang 
1 (YY1), a ubiquitously distributed TF largely known for its ability to modify histones 
(Karki, Kim et al. 2015, Karki, Smith et al. 2015). Glutamate has been shown to increase 
binding of YY1 to the GLAST/EAAT1 promoter, resulting in the negative regulation of 
GLAST/EAAT1 promoter activity in a time and dose-dependent manner (Karki, Kim et 
al. 2015). YY1 overexpression led to decreases in GLAST/EAAT1 mRNA and protein 
	 25 
levels (Rosas, Vargas et al. 2007, Aguirre, Rosas et al. 2008). Calcium-activated calpain 
proteases have been described to cleave and decrease the availability of YY1 in human 
vascular smooth muscle cells (Stoeckius, Erat et al. 2012), which would suggest calcium 
influx would increase GLAST/EAAT1 expression in astrocytes if this regulation were 
translatable. However, direct action of CaMKII on YY1 has not been described to date.   
It is noteworthy that an independent study observed an increase in glutamate 
uptake and increased GLAST expression in rodent cortical astroglial cultures under 
similar conditions (Gegelashvili, Civenni et al. 1996) in contrast to a larger body of data 
that suggests GLAST expression is downregulated upon glutamate application. These 
differences observed may be due to a culture that is enriched in GLAST, namely 
Bergmann glia, versus a culture that expresses predominantly GLAST, but GLT-1 
induction can occur in. Interestingly, this study observed an increase in only GLAST 
protein but not mRNA, suggesting this regulation is a result of translational, and not 
transcriptional, alterations in GLAST/EAAT1. Thus, it appears that glutamate can control 
the expression of GLAST/EAAT1 via the involvement of a number of transcription 
factors such as AP-1, CREB, YY1, and C-Jun. At least three of these (AP-1, CREB, C-
Jun) are regulated by CaMKII, which may provide a basis for a long-term regulatory 
effect and associated gene changes in GLAST/EAAT1 as a result of CaMKII alterations.  
 
YY1-associated regulation of GLAST/EAAT1 expression through effectors other than 
glutamate 
We previously described that glutamate induces a reduction in GLAST/EAAT1 
promoter activity through the transcription factor YY1 (Rosas, Vargas et al. 2007). 
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Valproate, a fatty acid used as a therapeutic for epilepsy and manic-depression, has been 
shown to elicit a dual regulatory effect on GLAST/EAAT1 promoter activity through 
YY1 via the induction of histone deacetylases (HDACs), which repress YY1 (Aguirre, 
Rosas et al. 2008). Recently manganese, a trace element that accumulates and acts as a 
neurotoxin in a number of neurological diseases, has been implicated in the reduction of 
GLAST/EAAT1 expression via YY1 binding to the GLAST/EAAT1 promoter. Thus, 
regardless of the mode of activation, YY1 appears to be key in negatively regulating 
GLAST/EAAT1 activity. Interestingly, YY1 represses GLT-1/EAAT2 expression; thus 
suggesting YY1 regulation of the two astrocytic glutamate transporters confers a similar 
effect (Karki, Kim et al. 2015, Karki, Smith et al. 2015). 
The nuclear factor-κB (NF-κB) is thought to be a positive regulator of 
GLAST/EAAT1 expression by its ability to bind the GLAST/EAAT1 promoter. The 
EAAT1 promoter contains two consensus sites for NF-κB. In particular, mutation of NF-
κB binding sites or inhibition of NF-κB decreased EAAT1 promoter activity while 
activation of NF-κB increased EAAT1 promoter activity, mRNA and protein levels 
(Karki, Kim et al. 2015). In fact, activation of intracellular Ca2+ and CaMKII have been 
shown to mediate NF-κB at multiple levels in neurons, T cells, and macrophages 
(Hughes, Edin et al. 2001, Ishiguro, Green et al. 2006, Liu, Yao et al. 2008). Although 
our studies did not examine long-term effects of CaMKII inhibition or activation on 
GLAST/EAAT1 levels, the transcription factor NF-κB appears to be a key player in this 
mechanism. In fact, long-term treatment (7 days) of mixed astroglial cultures with 
glutamate has been shown to increase GLAST expression and glutamate uptake 
(Gegelashvili, Civenni et al. 1996), contrary to the GLAST decrease elicited by a shorter 
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exposure to glutamate. It is conceivable that the opposing action of multiple transcription 
factors at play may lead to differential phenotypes when it comes to GLAST/EAAT1 
expression, and furthermore, this may be dependent on cell type and duration of 
glutamate treatment.  
 
Involvement of other transcription factors in GLAST/EAAT1 expression  
Using gel shift and supershift analyses of a portion of the cloned GLAST/EAAT1 
promoter from human fetal astrocytes, Kim et al (Kim, Choi et al. 2003) observed that 
stimulating protein (Sp) 1 and 3 bound to the GC-box in the GLAST/EAAT1 promoter. 
Sp proteins have been shown to play a role in transcriptional activation or repression of 
promoters lacking TATA or CAAT consensus sequences. Furthermore, upstream 
stimulating factor (USF1), a transcription factor that serves as a transcriptional activator, 
bound to the Enhancer (E) box in the GLAST/EAAT1 promoter. Although a number of 
other sites such as an X-box for protein RFX1, sites for the gut-enriched Krueppel-like 
factors, the serum response factor (SRF) and AREB6 were predicted, functional data 
suggested that these regulatory elements did not represent functional DNA-protein 
binding sites. These factors appear to be important for basal GLAST/EAAT1 activity.  
A number of studies observed that application of a cAMP analogue, EGF and 
TGF-α resulted in increased GLAST/EAAT1 mRNA, protein and subsequent glutamate 
uptake in astrocyte cultures, while demonstrating TNF-α downregulated endogenous 
GLAST/EAAT1 mRNA and protein, suggesting transcriptional regulation of the 
GLAST/EAAT1 promoter by these factors (Gegelashvili, Civenni et al. 1996, Swanson, 
Liu et al. 1997, Zelenaia and Robinson 2000, Kim, Choi et al. 2003). The role of CREB 
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in the involvement of EGF-mediated GLAST/EAAT1 changes was tested, but the authors 
suggest this phenomenon occurs independent of CREB-involvement (Schluter, Figiel et 
al. 2002). A recent study demonstrated the involvement of NF-κB in GLAST/EAAT1 
upregulated by EGF, suggesting it serves as a positive regulation of EAAT/1GLAST 
expression (Karki, Kim et al. 2015). However, for the most part, the transcriptional 
machinery that underlies the regulation of EAAT/1GLAST by growth factors and cAMP 
has not been elucidated. 
 
PACAP regulation of GLAST and GLT-1 expression 
The neuronally synthesized protein pituitary adenylate cyclase-activating 
polypeptide (PACAP) has been implicated in neuroprotection and shown to upregulate 
both GLAST and GLT-1 protein expression and subsequently increase maximum 
velocity of glutamate uptake in cortical glial cultures. Furthermore, PKA activation was 
necessary during a PACAP-mediated increase in GLAST expression, whereas a PACAP-
mediated increased in GLT-1 expression required both PKC and PKA activation (Figiel 
and Engele 2000, Goursaud, Maloteaux et al. 2008). In particular, utilization of a PACAP 
analogue suggested an increase in GLAST surface expression (Goursaud, Maloteaux et 
al. 2008). In a PACAP-type 1 receptor (PAC1) knockout mouse, a reduction in GLAST 
mRNA was observed in the dentate gyrus region of the hippocampus but no significant 
GLAST changes were observed in the cortex whereas no changes were observed in GLT-
1 in any brain regions, thus suggesting differential regulation of astrocytic glutamate 
transporters by PACAP (Zink, Schmitt et al. 2004). Thus far, further signaling pathways 
related to PACAP regulation of GLAST and GLT-1 have not been elucidated; however it 
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is clear that GLAST is clearly regulated by PACAP whereas GLT-1 regulation may be 
dependent on the model system being studied.  
 
GLT-1/EAAT2 promoter regulation by neuronal factors 
Although GLT-1/EAAT2 is expressed at high levels in brain tissue, it is expressed 
at low levels in pure astrocyte cultures (Gegelashvili, Danbolt et al. 1997, Swanson, Liu 
et al. 1997, Schlag, Vondrasek et al. 1998). Co-culturing astrocytes with neurons induced 
expression of GLT-1/EAAT2 (Gegelashvili, Danbolt et al. 1997, Swanson, Liu et al. 
1997, Schlag, Vondrasek et al. 1998). Concurrently, the astrocytes developed a stellate 
morphology, suggesting differentiation in vitro (Swanson, Liu et al. 1997, Schlag, 
Vondrasek et al. 1998). Independent studies observe decreases in GLT-1/EAAT2 
expression following rodent glutamatergic denervation and de-afferentiation, 
strengthening the idea that neurons contribute to the expression of the glutamate 
transporters (Ginsberg, Martin et al. 1995, Levy, Lehre et al. 1995). Astroglial cultures 
supplemented with conditioned media from neurons or separation of the glial cultures 
from neurons by a semi-permeable membrane produced a similar increase in GLT-
1/EAAT2 expression, without altering GLAST/EAAT1 levels (Gegelashvili, Danbolt et 
al. 1997). Collectively these data suggest neurons and/or neuronal factors regulate the 
expression of GLT-1/EAAT2.  
A number of soluble factors, primarily cytokines and growth factors, have been 
implicated in the induction of GLT-1/EAAT2 expression. Epidermal growth factor 
(EGF), the transforming growth factor-α (TGF-α), and cyclic adenosine monophosphate 
(cAMP) analogs induced GLT-1/EAAT2 steady-state mRNA and promoter activity, 
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while TNF-α decreased expression, and the platelet-derived growth factor had no effect 
(Swanson, Liu et al. 1997, Zelenaia, Schlag et al. 2000, Su, Leszczyniecka et al. 2003, 
Sitcheran, Gupta et al. 2005). No effects were observed when using insulin, basic 
fibroblast growth factor, and nerve growth factor (Eng, Lee et al. 1997, Schlag, 
Vondrasek et al. 1998, Zelenaia, Schlag et al. 2000). The GLT-1/EAAT2 promoter 
contains a number of putative transcription factor binding sites, including NF-κB, N-myc, 
and NFAT (nuclear factor of activated cells) (Zelenaia, Schlag et al. 2000, Su, 
Leszczyniecka et al. 2003, Yamamoto and Gaynor 2004). Deletion of the site where NF-
κB binds to the GLT-1/EAAT2 promoter reduced basal GLT-1/EAAT2 promoter activity 
as well as abolished elevations due to EGF, TGF-α, and cAMP analogs (Su, 
Leszczyniecka et al. 2003, Sitcheran, Gupta et al. 2005). N-myc recruitment to the GLT-
1/EAAT2 promoter has been implicated as a key event in the TNF-α associated decrease 
in GLT-1/EAAT2 expression (Sitcheran, Gupta et al. 2005).  
A number of signaling transduction pathways have been implicated or confirmed 
related to the alterations in GLT-1/EAAT2 expression by neuronal factors. The activation 
of p42/44 MAP kinases have been shown to be important for the upregulation of GLT-
1/EAAT2, with neuronal conditional media resulting in the phosphorylation of 
transcription factors CREM-1 and ATF-1 (Swanson, Liu et al. 1997, Gegelashvili, 
Dehnes et al. 2000). Inhibitors of PI3K, NF-κB, and tyrosine kinase blocked an increase 
in GLT-1/EAAT2 mediated by neuronal conditioned media (Swanson, Liu et al. 1997, 
Zelenaia, Schlag et al. 2000). These data suggest numerous independent signaling 
pathways mediate the induction of GLT-1/EAAT2. Given the commonality in  
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transcription factors implicated in this mechanism, it is possible that these pathways may 
converge at some point along the signaling cascade.  
 
GLT-1/EAAT2 promoter regulation by ceftriaxone 
Ceftriaxone, a third-generation cephalosporin antibiotic traditionally used as an 
antimicrobial, was found to be a potent neurotherapeutic by enhancing GLT-1/EAAT2 
expression (Rothstein, Patel et al. 2005). Although ceftriaxone recently failed to 
demonstrate efficacy in a stage 3 randomized, double-blind trial to treat amyotrophic 
lateral sclerosis (Berry, Shefner et al. 2013, Cudkowicz, Titus et al. 2014), it has been a 
recent promising therapeutic targeting glutamate transporter expression. Since its initial 
fortuitous discovery as a neuroprotective agent, numerous studies have been performed 
demonstrating the ability of ceftriaxone to diminish neuronal loss associated with a 
variety of pathological states. These include (but aren’t restricted to) ceftriaxone’s ability 
to: delay muscle loss and neuronal death in a murine model of ALS (Melzer, Meuth et al. 
2008), reduce neurodegeneration and associated motor deficits in animal models of stroke 
(Lipski, Wan et al. 2007, Thone-Reineke, Neumann et al. 2008), alleviate chronic 
neuropathic pain in rodents (Hu, Li et al. 2010) and decrease post-traumatic TBI-
associated seizures. Mechanistically, ceftriaxone upregulates GLT-1/EAAT2 mRNA and 
protein expression (Rothstein, Patel et al. 2005, Chu, Lee et al. 2007). In primary human 
fetal astrocytes, this increase was mediated through the NF-κB transcription factor 
signaling pathway. Specifically, this study found that nuclear translocation of p65 and 
binding of NF-κB to the -272 position of the EAAT2 promoter were necessary for 
EAAT2 induction mediated by ceftriaxone (Lee, Su et al. 2008). Further interest in the 
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transcriptional machinery regulating ceftriaxones role in effecting GLT-1/EAAT2 
expression may dwindle owing to failure of late-stage clinical trials in an ALS model, 
however it is clearly that at least NF-κB is a key transcription factor involved in this 
mechanism. 
 
GLT-1/EAAT2 promoter regulation by estrogen receptors 
Exposure of primary astrocytes to estrogen resulted in significant increase in 
GLAST and GLT-1 mRNA and protein levels, and increased glutamate uptake (Pawlak, 
Brito et al. 2005). Recently, the specific mechanisms underlying these phenotypes have 
been elucidated. Tamoxifen and raloxifene, selective estrogen receptor modulators, and 
estradiol, an endogenous type of estrogen, were found to upregulate GLT-1 expression 
and function via TGF-α (Karki, Webb et al. 2013, Lee, Sidoryk-Wegrzynowicz et al. 
2013, Karki, Smith et al. 2014, Karki, Webb et al. 2014). Specifically, tamoxifen induced 
the activation of PKA, which in turn phosphorylates CREB to recruit the transcription 
factor to the GLT-1 promoter. Inhibition of either PKA or NF-κB abolished a tamoxifen-
mediated increase in GLT-1 promoter activity. The effect of tamoxifen on GLT-1 
expression was completely blocked when both CREB and NF-κB binding sites were 
inhibited at the same time (Karki, Webb et al. 2013). Raloxifene has been shown to 
upregulate GLT-1 mRNA and protein via multiple signaling pathways: ERK, EGFR, and 
CREB. Furthermore, raloxifene induces an increase in NF-κB reporter activity and leads 
to direct binding of the transcription factor to the GLT-1 promoter (Karki, Webb et al. 
2014). Thus, based on the ligand, it appears that a number of different pathways are 
important in mediating GLT-1 expression. As most of the studies delineating signaling 
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pathways are recent, emerging literature may shed more light on the convergence, 
divergence or overlap in these pathways.  
 
Translation 
Unlike EAAT1, a number of studies report alterations in EAAT2 expression in 
pathological states where mRNA is not disrupted, suggesting disturbances may occur at 
the post-transcriptional or translational level (Rothstein, Van Kammen et al. 1995, Bristol 
and Rothstein 1996, Masliah, Alford et al. 1996). Protein non-coding mRNA regions 
(UTRs) have been shown to play important roles in regulation of gene expression, and 
these alterations are thought to occur post-transcriptionally. In fact, UTRs regulate 
mRNA stability, subcellular localization, nuclear export to the cytoplasm, alternate 
splicing of gene products, and translational efficiency (reviewed in (Grewer, Gameiro et 
al. 2014)). EAAT1ex9skip, named so since it lacks the entirety of exon 9, has thus far 
been the only splice variant described for EAAT1 (Vallejo-Illarramendi, Domercq et al. 
2005). Multiple GLT-1/EAAT2 transcripts have been identified based on differences in 
untranslated UTRs that result in differential splice variants of this transporter (Pines, 
Danbolt et al. 1992, Arriza, Fairman et al. 1994, Utsunomiya-Tate, Endou et al. 1997, 
Chen, Aoki et al. 2002, Schmitt, Asan et al. 2002, Rauen, Wiessner et al. 2004, Tian, Lai 
et al. 2007). Extracellular factors, such as corticosterone, retinoic acid and β-lactam 
antibiotics, have been shown to induce the translation of some of these EAAT2 
transcripts, which may not occur in a constitutive manner (Tian, Lai et al. 2007). Thus, a 
number of splice variants exist that are differentially regulated.  
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Translational effects on the glutamate transporters are now serving as the basis for 
devising neurotherapeutics to increase EAAT2 expression and thus reduce aberrant 
glutamatergic neurotransmission. For example, primary astrocyte-based enzyme-linked 
immunosorbent assay was devised to identify compounds that serve as translational 
activators of EAAT2 expression (Colton, Kong et al. 2010). This study identified 61 
compounds that demonstrated a dose-dependent increase in EAAT2 protein levels. 
Studies involving translational enhancement of transporter may serve useful in the future 
as increasing glutamate uptake can serve to minimize detrimental effects during 
pathological states.  
 
Post-translation modifications 
Phosphorylation 
Phosphorylation refers to the addition of a phosphoryl group to an amino acid 
(typically a serine/threonine/tyrosine as they have a free hydroxyl group) onto a protein 
by a kinase. Functional changes in a membrane transporter may occur due to direct 
phosphorylation of the protein, or indirect phosphorylation of an interacting scaffolding 
protein or a downstream protein or kinase that may directly regulate the transporter by 
another mechanism. Phosphorylation of transcription factors that leads to their 
recruitment to the glutamate transporter promoter has been addressed in a previous 
section. Interestingly, the activation of PKC in Bergmann glia cells, which predominantly 
express GLAST, results in a reduction in GLAST-mediated glutamate uptake. Studies 
reported either a reduction or no alteration in membrane trafficking of GLAST upon PKC 
activation (Conradt and Stoffel 1997, Wang, Li et al. 2003). Mutation of the putative 
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PKC sites on GLAST did not reverse this decrease in transporter activity, which the 
authors attributed to phosphorylation of a non-consensus PKC site. However, it is also 
possible that PKC may be acting through another protein that regulates GLAST directly 
(Conradt and Stoffel 1997). Interestingly, an increase in GLT-1 mediated glutamate 
uptake has been observed upon application of TPA, a potent phorbol ester that activates 
PKC (Casado, Zafra et al. 1991). This group further demonstrated this increase in 
glutamate uptake was mediated via phosphorylation of a specific residue, Ser116 in an 
intracellular loop on GLT-1 in virally infected HeLa cells, thus upregulating glutamate 
uptake. Mutation of this residue resulted in a reduction in GLT-1 mediated glutamate 
uptake by ~50%, suggesting its importance in this process (Casado, Bendahan et al. 
1993).  
 
Glycosylation  
Glycosylation refers to the enzymatic addition of a glycan to a residue on the 
extracellular domains of a protein. This PTM is added during maturation of nascent 
polypeptides in the Golgi apparatus and the endoplasmic reticulum, and can influence 
protein folding, endocytosis, molecular trafficking, and signal transduction (Raunser, 
Haase et al. 2005, Sattler and Rothstein 2006). Clinical data demonstrate decreased 
glycosylation for both GLAST/EAAT1 and EAAT2 proteins in the prefrontal cortex of 
patients with schizophrenia compared to health controls (Bauer, Haroutunian et al. 2010). 
Interestingly, increased mRNA expression and decreased protein expression of EAAT1 
have been described in the prefrontal cortex of schizophrenic patients (Bauer, Gupta et al. 
2008), suggesting reductions in glutamate uptake can contribute to disease pathology. 
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Since glycosylation is important for the localization and targeting of proteins, alterations 
may affect transporter function during schizophrenia. 
In Xenopus laevis oocytes, GLAST was found to be glycosylated at two residues 
located in the extracellular loop between transmembrane helices 3 and 4 (Conradt, Storck 
et al. 1995). Mutation of these residues appeared to have no effect on transporter activity, 
measured using voltage clamp, in oocytes suggesting glycosylation at these sites in 
particular is not crucial for GLAST function. However, another study found that a highly 
glycosylated form of GLAST resulted in the re-distribution of the transporter into raft 
functional membrane microdomains, which improves the ability of a cell to buffer 
glutamate (Escartin, Brouillet et al. 2006). Thus, while it appears that particular 
glycosylation residues may not contribute to GLAST activity, the overall glycosylation 
state of the transporter may be crucial in order to uptake glutamate. Further studies are 
needed in order to clarify these findings.  
The contribution of glycosylation in EAAT2 function paints a conflicting picture. 
Studies by Kalandadze et al. (Kalandadze, Wu et al. 2002) suggest a 43-amino acid 
region including the last trans-membrane domain and part of the C-terminus region (475-
517) is important for functionality of the GLT-1 transporter in astrocytes. Furthermore, 
they observed that this motif contains a leucine-rich region that suppresses a downstream-
arginine based motif that serves as an ER retention motif. Mutation of the leucine-rich 
region causes retention of the GLT-1 transporter in the ER, leading to immature 
unglycosylated transporter that ultimately results in aberrant trafficking and confers a 
dominant-negative effect over wild-type transporter (Kalandadze, Wu et al. 2004). These 
data suggest increases in ER retention may account for decreased membrane expression 
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and uptake by transporter in GLT-1 lacking glycosylation (Trotti, Aoki et al. 2001). 
However another study reports that glycosylation of GLT-1 did not result in differences 
in liposomal reconstitution, trafficking or transporter activity compared to a non-
glycosylated form of the same protein, thus making it hard to reconcile a singular 
functional effect associated with GLT-1 glycosylation. Interestingly, in this study, GLT-1 
glycosylation appeared to enhance protein stability over time in vitro but did not affect its 
ability to form heteromers, suggesting glycosylation may play a more long-term role in 
cellular GLT-1 expression (Raunser, Haase et al. 2005).  
 
Ubiquitination 
Ubiquitin is a 76 amino acid long post-translational modifier that is associated 
with protein internalization, endosomal sorting, and proteosomal or lysosomal 
degradation (reviewed in (Kim and Rao 2006)). Prolonged activation of PKC using 
phorbol esters resulted in decreased surface expression of GLT-1 (Sheldon, Gonzalez et 
al. 2008, Garcia-Tardon, Gonzalez-Gonzalez et al. 2012). This phenotype appears to be 
mediated by internalization and ubiquitination of the GLT-1 protein (Sheldon, Gonzalez 
et al. 2008, Martinez-Villarreal, Garcia Tardon et al. 2012). Although both the N- and C-
termini of GLT-1 contain ubiquitinated lysine residues, only the C-terminus lysine 
residues are required for GLT-1 endocytosis (Gonzalez-Gonzalez, Garcia-Tardon et al. 
2008, Sheldon, Gonzalez et al. 2008). Although reports examining the contribution of 
ubiquitin as a post-translational modifier of glutamate transporter activity are limited, 
these findings suggest it may play an important role in activity-dependent alterations in 
glutamate uptake.  
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Sumoylation 
SUMOylation is a PTM wherein a Small Ubiqutin-like Modifier (SUMO) is 
covalently attached or detached to lysine residues in target proteins, resulting in cellular 
changes, ranging from protein stability to transcriptional regulation and cell cycle 
progression. Initial findings in a mouse model of ALS suggested that SUMO1-conjugated 
C-terminal fragments of EAAT2 were associated with motor neuron impairment. 
Furthermore, SUMO-conjugated proteolytic fragment of EAAT2 was found to 
accumulate in the nucleus of spinal cord astrocytes (Foran, Bogush et al. 2011). 
However, a recent study has suggested that sumoylation of EAAT2 govern its 
intracellular compartmentalization and are not driven by pathological mechanisms. This 
idea is further strengthened by the presence of non-sumoylated EAAT2 on the plasma 
membrane (Foran, Rosenblum et al. 2014), lending credence to the idea that sumoylation 
of EAAT2 drives it to traffick intracellularly. 
 
Binding 
Glutamate transporter activity can be affected by glutamate transporter associated 
proteins, or GTRAPs. In fact, GTRAP41 and GTRAP48 increase the Vmax of glutamate 
uptake via EAAT4 (Jackson, Song et al. 2001). Furthermore, EAAC1 has been shown to 
interact with GTRAP3-18 (Lin, Orlov et al. 2001), decreasing the affinity of EAAC1 for 
glutamate (from 9µM to 40µM) and reducing EAAC1 mediated glutamate transporter 
activity. GTRAP3-18, a binding partner of EAAT3, is a regulator of ER trafficking and 
thus plays a role in transporter maturation (Ruggiero, Liu et al. 2008). 
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Recently, Underhill et al. observed that calcium/calmodulin-dependent protein 
kinase phosphorylation of Discs large homolog 1 (DLG1), a PDZ protein, decreased 
surface expression of a splice variant of EAAT2 in both Madin-Darby canine kidney cells 
and cultured astrocytes. The authors propose a mechanism whereby DLG1 
phosphorylation disrupts its PDZ-mediated interaction and its function as a scaffold, thus 
preventing stabilization of EAAT2 at the cell surface (Underhill, Wheeler et al. 2015). 
Thus, it appears that signaling changes associated with proteins that interact with or 
stabilize the glutamate transporters can disrupt either localization and/or activity of 
glutamate transporters. 
  
Trafficking 
The rate of membrane protein recycling is dependent on the rate of transporter 
delivery and re-internalization to and from the plasma membrane. Thus, at steady-state, if 
the rate of delivery to the plasma membrane is greater than the rate of internalization, 
then there will be an increase in the number of transporters at the plasma membrane. 
Conversely, if the rate of internalization is greater than the rate of delivery, then there 
will be a decrease in the number of transporters at the plasma membrane. Thus, rapid 
alterations in glutamate transporter activity are dependent on an intracellular pool of 
transporters.  
The most extensively studied glutamate transporter with regards to trafficking is 
the neuronal transporter EAAC1/EAAT3, which has been shown to reside primarily in 
intracellular pools (Kalandadze, Wu et al. 2002). However, for the purposes of this 
dissertation I will continue focusing on GLAST/EAAT1 and GLT-1/EAAT2, the 
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predominant glutamate transporter in astrocytes. The primary literature is, however, not 
in agreement about the basal localization of astrocytic glutamate transporters. Some 
studies suggest 60-80% of total transporter immunoreactivity (both GLAST/EAAT1 and 
GLT-1/EAAT2) is localized to the cell surface in both primary astrocytes and mixed 
astroglial/neuronal cultures (Sclag 1998, Kalandadze 2002, Susarla 2004). However, 
other reports suggest that both these transporters do not exhibit intracellular 
immunoreactivity rodent brain slices, providing evidence that the transporter resides 
exclusively at the cell surface (Chaudhry, Lehre et al. 1995, Lehre, Levy et al. 1995). Yet 
other studies observe that GLAST and GLT-1 are found intracellularly (Duan, Anderson 
et al. 1999, Guillet, Velly et al. 2005). One possibility that arises from these findings is 
that the distinction between intracellular (or located in a cellular compartment) compared 
to in the plasma membrane may not be quite as straightforward as one would imagine- 
the transporters may residue just under the surface of the plasma membrane, making them 
rapidly accessible at the membrane when needed but not detectable in an intracellular 
compartment. Furthermore, it is conceivable that the localization of GLAST/EAAT1 and 
GLT-1/EAAT2 may depend on the model system, cell type, and even the culture or 
treatment conditions. While complex mechanisms may underlie these observations, what 
is clear is that numerous signaling pathways regulate trafficking of these transporters to 
and from the plasma membrane, rapidly altering glutamate transporter activity.  
 
Trafficking of GLAST/EAAT1 
GLAST/EAAT1 has been reported to rapidly traffick into and out of the 
membrane. Although thus far we have focused on the transcriptional regulation of 
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GLAST expression by glutamate, these changes occur in the order of a few hours. A 
number of independent studies report rapid increases (>30 mins) in GLAST trafficking to 
the membrane as the mechanism underlying augmented glutamate uptake as a result of 
glutamate addition. In particular, glutamate appears to increase the cell-surface 
expression of GLAST in primary mouse astrocyte cultures (Duan, Anderson et al. 1999). 
This time and dose-dependent increase in glutamate-induced glutamate uptake was 
attributed to actin polymerization, as inhibitors of actin polymerization reversed this 
effect. An additional study reported that the presence of neurons affects the glutamate 
uptake capacity of GLAST and GLT-1 (Poitry-Yamate, Vutskits et al. 2002). 
Specifically, this study demonstrates that the release of neuronal glutamate results in an 
increase clustering of GLAST in astrocyte cultures as measuring by immunofluorescence. 
Importantly, within a matter of a few minutes, GLAST trafficks to the membrane and 
results in increased glutamate uptake, providing evidence for an activity-dependent and 
substrate-induced regulation of transporter activity. Transcriptional data suggests that 
GLAST is not retained at the membrane, and over time decreased GLAST expression 
may be modulated by transcription factors. 
Furthermore, signaling molecules have been implicated in alterations in 
GLAST/EAAT1 surface expression. For example, PKC activation has been shown to 
increase glutamate uptake in cortical astrocytic cultures from the rat forebrain (Casado, 
Zafra et al. 1991, Guillet, Velly et al. 2005) a model system where glutamate uptake is 
primarily mediated by GLAST/EAAT1 unless GLT-1/EAAT2 expression is induced 
(Gegelashvili, Danbolt et al. 1997, Gegelashvili and Schousboe 1997). However, this 
particular study did not examine surface expression of the glutamate transporters, as at 
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the time the molecular identity underlying astrocytic glutamate transport was unknown. 
Subsequent studies examined the phenotype underlying PKC regulation of glutamate 
transporters. A PKC-induced increase in glutamate uptake was attributed to increased cell 
surface expression of GLAST/EAAT1 in a neuron-enriched astrocyte culture (Guillet, 
Velly et al. 2005). However, linking surface expression of the glutamate transporter to 
alterations in glutamate uptake were not always straightforward. In primary astrocyte 
cultures derived from the forebrain, although a similar increase in glutamate uptake was 
observed upon PKC activation, an unexpected decrease in both total lysate and surface 
fraction of GLAST/EAAT1 was reported, measured by biotinylation experiments 
(Susarla, Seal et al. 2004). Although the authors attribute these findings to the masking of 
GLAST/EAAT1 epitopes as a result of PKC activation, it is possible that 
GLAST/EAAT1 may be rapidly re-distributed into intracellular compartments that are 
inaccessible by the antibodies used in the study. In addition, it appears that in different 
culture systems, PKC activation may have varied effects on GLAST-mediated glutamate 
uptake. For example, in primary cultures of retinal Muller cells, which express primarily 
GLAST/EAAT1, a decrease in glutamate uptake and GLAST surface expression was 
observed upon PKC activation (Wang, Li et al. 2003). It is clear that PKC regulation of 
glutamate transport is thus a complex phenomenon. One possible explanation of these 
data is that in cultures where GLAST/EAAT1 is the primary glutamate transporter, PKC 
may result in a decrease and not an increase in glutamate uptake, as is observed in mixed 
cultures that express both GLAST/EAAT1 and GLT-1/EAAT2. Thus, the type of cell 
used and supporting culture conditions are important when considering the effect of a 
signaling pathway on glutamate uptake. Regardless of the interpretation underlying 
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differential phenotypes related to GLAST/EAAT1 trafficking, numerous studies suggest 
that the protein can be rapidly inserted into and removed from the membrane. 
 
Trafficking of GLT-1/EAAT2 
PKC activation of GLT-1/EAAT2 appears to consistently decrease cell surface 
expression and activity of the transporter, whether it is in a mixed neuron/astrocyte 
culture system or in transfected glioma cells (Kalandadze, Wu et al. 2002, Zhou and 
Sutherland 2004, Guillet, Velly et al. 2005). In particular, a 43-amino acid region in the 
C-terminus of GLT-1/EAAT2 was found to be important for PKC-mediated re-
distribution of the transporter (Kalandadze, Wu et al. 2002). Mutation of serine 486 in 
this domain, however, only partially prevented transporter internalization and a reduction 
in phosphorylation of the transporter was not detected in the mutant transporter. These 
data suggest that while phosphorylation may play a role in the rapid trafficking of GLT-
1/EAAT2 from the membrane, other potential phosphorylation sites or an additional 
method of regulation not identified by this study are important for the PKC-dependent re-
distribution of GLT-1/EAAT2.  
A recent study demonstrates that a splice variant of EAAT2 referred to as 
EAAT2b can be rapidly trafficked to the membrane as a result of glutamate-induced 
calcium signaling (Underhill, Wheeler et al. 2015). This study implicated the stabilization 
of EAAT2 by a scaffolding protein DLG1, which upon phosphorylation by CaMKII can 
rapidly internalize the transporter from the membrane. In support of this finding, the 
neuronal release of glutamate leads to the formation of GLT-1 clusters that localize near 
neurons (Poitry-Yamate, Vutskits et al. 2002). A recent report suggests rapid alterations 
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in synaptic activity affect the trafficking of GLT-1/EAAT2 to the membrane and shape 
fast synaptic transmission, which may provide a basis for the ability of GLT-1/EAAT2 
appears to rapidly re-distribute in an activity-dependent manner (Murphy-Royal, Dupuis 
et al. 2015).  
 
It is evident that both the astrocytic glutamate transporters can thus be regulated 
in various ways, by the addition of extracellular and modifying intracellular signaling 
molecules or transcription factors, in order to affect glutamate uptake. Thus far, the 
majority of this dissertation has dealt with the EAATs in a physiological context. In order 
to fully understand their role in the CNS, we must next address transporter function in a 
pathological context.   
 
Pathological dysregulation of the astrocytic glutamate transporters 
Ischemia 
Thermodynamically favorable ionic flux associated with the astrocytic glutamate 
transporters results in the influx of 1 glutamate-, 3 Na+ molecules and 1 H+, while a K+ 
ion is counter-ported. However, during conditions of ischemia glutamate transporter 
reversal has been described, leading to elevations in extracellular glutamate levels due to 
the release of glutamate instead of uptake by astrocytes (Phillis, Ren et al. 2000). This 
phenotype contributes to an increase in the concentration of extracellular glutamate, and 
increased excitotoxicity via the aberrant activation of glutamate receptors.  
In addition, a number of studies have reported decreased expression of GLT-1 
without observing changes in GLAST after cerebral ischemia in rodents, both at the level 
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of mRNA as well as protein (Bruhn, Levy et al. 2000, Yeh, Hwang et al. 2005, 
Ketheeswaranathan, Turner et al. 2011). Furthermore, decreases in GLT-1 protein have 
been reported following an hour of oxygen-glucose deprivation in hippocampal astrocyte 
cultures (Ouyang, Voloboueva et al. 2007). Combinatorial changes such as these likely 
contribute to diminished glutamate clearance by astrocytes during ischemic conditions. 
 
Traumatic brain injury  
In traumatic brain injury (TBI), increases in extracellular glutamate in the brain 
and spinal cord have been reported in both animal models and humans. Not surprisingly, 
a reduction in both GLAST and GLT-1 protein levels has been reported following 
controlled cortical impact in the hippocampus of rodents, concomitant with a decrease in 
radiolabeled aspartate uptake (Rao, Baskaya et al. 1998), suggesting the function of both 
astrocytic proteins is dysregulated during TBI. Additionally, knockdown of GLT-1 using 
antisense oligodeoxynucleotides has been shown to exacerbate neuronal death associated 
with a controlled cortical impact model of injury (Rao, Dogan et al. 2001). In a study 
involving TBI patients, a significant reduction in both astrocytic EAAT1 and EAAT2 
levels was observed, which was attributed to astrocyte degeneration and downregulated 
protein in surviving astrocytes (van Landeghem, Weiss et al. 2006). Thus, the effects of 
TBI thus far appear to be chronically regulated as they primarily ascribe a reduction in 
transporter function to reductions in protein levels. Glutamate transporter reversal, a key 
mechanism of glutamate extrusion from astrocytes during pathological conditions, has 
not been described during TBI to date (Yi and Hazell 2006).  
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Alzheimer’s disease 
Alzheimer’s disease, a chronic neurodegenerative condition marked by the 
formation of neurofibrillary plaques and tangles, is associated with excitotoxic neuronal 
death, decreased glutamate transporter expression and a reduction in glutamate uptake 
(Mookherjee, Green et al. 2011). A reduction in glutamate transporter uptake was 
correlated with cognitive decline (Masliah, Alford et al. 1996), and a restoration of a glial 
glutamate transporter in a mouse model increased synaptic integrity and benefited 
cognitive function (Takahashi, Kong et al. 2015). Reduced expression of GLAST and 
GLT-1 have been reported in brain tissue from at least two separate murine models of 
Alzheimer’s disease, resulting in alterations in glutamatergic neurotransmission 
(Schallier, Smolders et al. 2011, Cassano, Serviddio et al. 2012).  
 
Amyotrophic lateral sclerosis  
Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative disease 
characterized by upper and lower motor neuron degeneration (Rothstein, Tsai et al. 
1990). A 100-200% increase in extracellular glutamate concentrations has been reported 
in the cerebrospinal fluid of patients with ALS (Rothstein, Tsai et al. 1990). Specifically, 
high-affinity, sodium-dependent transport was decreased in synaptosomal preparations 
from the spinal cord, motor, and somatosensory cortices in patients with ALS (Rothstein, 
Martin et al. 1992). Selective loss of the astrocytic glutamate transporter GLT-1 has been 
implicated as the primary molecular defect accounting for dysregulated glutamate 
clearance and increased extracellular glutamate in the ALS pathology (Rothstein, Van 
Kammen et al. 1995, Howland, Liu et al. 2002). 
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Thus, dysregulated glutamatergic neurotransmission and in particular, glutamate 
uptake, have been described in numerous neurodegenerative conditions. While it is 
currently unknown what mechanisms underlie these disease states, a common theme in 
all of these pathological states is aberrant calcium signaling.  Next I explore the role of 
astrocytic calcium to identify potential mechanism that may contribute to the regulation 
of astrocytic glutamate uptake.  
 
Calcium signaling in astrocytes  
The ability of the neurotransmitter glutamate to induce astrocytic calcium 
oscillations and calcium waves was first observed within and among cultured astrocytes 
(Cornell-Bell, Finkbeiner et al. 1990, Charles, Merrill et al. 1991). Astrocytes are 
complex cells, and thus the sources of calcium oscillations and waves are numerous and 
are still being explored. Briefly, both ligand- and voltage-gated Ca2+ ion channels have 
been implicated in direct calcium influx into astrocytes. Furthermore, channels such as 
the TRP and Orai channels have been suggested to allow calcium entry as well 
(Shigetomi, Patel et al. 2016). Activation of astrocytic class I metabotropic receptors 
resulting in the opening of IP3-sensitive internal stores and ‘spiked’ calcium release, 
resulting in rapid propagation of a calcium response intercellularly via gap junctions 
(Kim, Rioult et al. 1994, Kawabata, Tsutsumi et al. 1996). Furthermore, this 
metabotropic response can also result in calcium oscillations of varied frequencies and 
amplitudes that are dependent on extracellular calcium (Kim, Rioult et al. 1994). 
Additionally, intracellular organelles and the mitochondria have been implicated in 
intracellular calcium release (Shigetomi, Patel et al. 2016). A number of signaling 
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molecules have since been shown to elevate astrocytic calcium in glia in brain slices: 
norepinephrine, GABA, acetylcholine, adenosine, ATP, and histamine (reviewed in 
(Haydon and Carmignoto 2006)). It is thus clear that there are numerous signaling 
methods that can result in the rise of intracellular calcium.  
 
CaMKII Structure 
The activation of intracellular calcium in an astrocyte using both glutamate and 
ionomycin has resulted in the activation of the calcium/calmodulin dependent kinase 
(CaMKII), a key calcium-dependent protein kinase (Yano, Fukunaga et al. 1994, Oguri, 
Inoko et al. 2006). CaMKII is a multifunctional serine/threonine protein kinase that 
comprises an N-terminal catalytic domain, an autoregulatory domain, a linker region, and 
a C-terminal association/hub domain. The catalytic domain of CaMKII contains an ATP 
binding pocket, the catalytic cleft, and the substrate targeting groove. In a basal state, the 
autoregulatory domain lies across the catalytic cleft, serving to inhibit CaMKII activity in 
the absence of calcium/calmodulin (Colbran, Schworer et al. 1989). Binding of the 
calcium-bound calmodulin protein to the C-terminal region of the autoregulatory domain 
displaces the autoregulatory domain from the catalytic cleft thus allowing ATP and 
substrate binding to occur (Colbran, Smith et al. 1989).  
The association or hub domains within each CaMKII subunit interact to form the 
hexagonal ring-like structure from which arm-like structures, or the catalytic heads of 
each subunit, radiate (Woodgett, Davison et al. 1983, Kanaseki, Ikeuchi et al. 1991). 
Resolving the crystal structure for human αCaMKII provided stronger evidence for this 
unique dodecameric organization of the kinase, with two hexameric rings stacked on top 
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of one another (Chao, Stratton et al. 2011). Eight to twelve individual subunits, each ~54 
to 72 kDa in size, come together to form the CaMKII holoenzyme, a protein ~600kDa in 
size (Kuret and Schulman 1984).  
A number of different ideas have been proposed that could underlie the 
multimeric nature of the enzyme. Different isoforms (addressed in greater detail in the 
next section) assembling into the same complex produce a composite holoenzyme that 
can display various combinations of intermediate calcium sensitivities and calcium spike 
frequency dependence. Furthermore, cellular localization of CaMKII could require 
domains created by association domain assembly. Additionally, co-assembly of multiple 
isoforms or splice variants can produce distinct localization based on different targeting 
sequences.  
 
CaMKII Expression 
Four isoforms α, β, γ, and δ CaMKII encoded by closely related genes have thus 
far been described for CaMKII. 30 splice variants of mammalian CaMKII exist. The 
molecular weight of the isoforms ranges from 54 to 72 kDa. Alignment of the 4 CaMKII 
isoforms results in >60% homology, with the catalytic domains in particular being highly 
conserved (>95%). Most unique among the isoforms and different associated splice 
variants is the variable domain region, part of the hub domain. These variable regions 
contain different substrate binding and cellular localization motifs (reviewed in 
(Soderling, Chang et al. 2001, Bradshaw, Hudmon et al. 2002, Hudmon and Schulman 
2002, Colbran and Brown 2004)).  
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CaMKII isoforms are expressed in a cellular, tissue, and sub-cellular specific 
manner (Hudmon and Schulman 2002). While αCaMKII and βCaMKII are primarily 
localized in brain tissue (Erondu and Kennedy 1985, Lucchesi, Mizuno et al. 2011), 
expression of αCaMKII has been reported in skeletal muscle, while βCaMKII is found in 
immune cells. δCaMKII and γCaMKII are present in most tissues, however δCaMKII 
predominates in cardiomyocytes, and γCaMKII is found in the lungs (Tobimatsu and 
Fujisawa 1989). In the central nervous system, αCaMKII and βCaMKII have been 
reported to predominate in neurons whereas δCaMKII and γCaMKII, while present in 
neurons albeit at much lower levels, have been reported to predominate in astrocytes 
(Ouimet, McGuinness et al. 1984, Bayer, Lohler et al. 1999). In the brain, αCaMKII has 
been reported to predominate cortically whereas βCaMKII is expressed at higher levels in 
the cerebellum (McGuinness, Lai et al. 1985). In addition, based on different cellular 
localization motifs, splice variants of the same CaMKII isoform can target to distinctive 
cellular compartments. For example, splice variants of some CaMKII isoforms can 
contain a nuclear localization sequence (NLS), as in the case of δB CaMKII (Zhang, 
Johnson et al. 2002). An NLS allows for translocation of CaMKII to the nucleus, where 
CaMKII is hypothesized to play a role in calcium-mediated gene transcription. 
 
Activation of CaMKII by Ca2+/CaM 
As mentioned previously, the autoinhibitory domain of CaMKII is tightly bound 
to the catalytic region and serves as a form of autoinhibition when calcium/calmodulin 
are not present. Thus, basal kinase activity levels remain at <1000 fold below their 
maximal calcium/calmodulin-stimulated activity. At a biochemical level, it has been 
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observed that the autoinhibitory domain of CaMKII contains residues that mimic a 
protein substrate interaction with the catalytic face of the kinase, thus deeming this a 
pseudosubstrate interaction. In this conformation, neither the ATP-binding pocket nor the 
substrate-binding pocket is available for their respective binding partners. The 
autoinhibitory region is N-terminal and contiguous to the calmodulin-binding sequence 
on CaMKII. Calcium/calmodulin binding to the autoregulatory domain exposes the 
catalytic cleft of the kinase, as suggested by the crystal structure of one active 
catalytic/autoregulatory domain. While no crystal structure exists for an activated form of 
the CaMKII holoenzyme, the crystal structure of the inactive holoenzyme suggests a 
drastic structural rearrangement needs to occur in order for calmodulin to bind with its 
binding site on CaMKII, buried deep within the CaMKII 3D structure (Hoffman, Stein et 
al. 2011). CaM binding occurs in an antiparallel and temporally distinct fashion, with the 
N-terminal lobe of CaM first forming a contact with the autoregulatory domain (C-
terminus) of CaMKII. If nucleotides are present, the C-terminal lobe will flex and bind to 
the N-terminal portion of CaMKII (Evans and Shea 2009, Jama, Gabriel et al. 2011). 
Interestingly, the N-lobe of CaM has been shown to partially activate the kinase, whereas 
the C-lobe of CaM is not required for CaMKII activation. Interestingly, in the presence of 
ATP, once ‘activated’, CaMKII’s affinity for bound Ca2+/CaM is enhanced by 1000-fold, 
from ~20nM to ~20pM (Meyer, Hanson et al. 1992, Forest, Swulius et al. 2008). 
 
CaMKII Autophosphorylation 
The autoregulatory domain of CaMKII contains a classical CaMKII consensus 
sequence (R-X-X-S/T), with Thr286 (in the α isoform, 287 in β, γ, and δ isoforms) being 
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the potential phosphorylation residue. Following CaMKII activation, CaMKII 
phosphorylates this residue (Lou and Schulman 1989). In fact, the unique dodecameric 
structure of CaMKII allows for each subunit of a holoenzyme to be in close proximity 
with another, and thus this phosphorylation event has been described to be an 
‘intersubunit autophosphorylation’ event (Mukherji and Soderling 1994, Bradshaw, 
Hudmon et al. 2002). Once CaMKII is autophosphorylated at Thr286, its activity 
becomes Ca2+/CaM-independent (Miller and Kennedy 1986, Lou and Schulman 1989). 
Thus, even when intracellular calcium returns to basal levels, CaMKII can function free 
from its normal stimulus in an autonomous state. Secondly, the affinity of CaMKII for 
CaM increases by 1000-fold. While the functional consequence of this CaM ‘trapping’ 
state has not been elucidated, it is possible that CaM-related cellular signaling might be 
altered due to its sequestration by CaMKII. Furthermore, once Thr286 is phosphorylated 
and Ca2+/CaM dissociate, the kinase is capable of autophosphorylating itself at 
Thr305/306 in the CaM-binding domain which can prevent further Ca2+/CaM activation 
of the kinase. 
The extent of a cells’ autonomous activity is important as ‘active’ CaMKII serves 
as a molecular memory device for calcium signals. Ca2+/CaM-independent activity as a 
function of Ca2+/CaM-dependent activity is experimentally measured to determine % 
autonomy (Saitoh and Schwartz 1985). CaMKII autophosphorylation is important in a 
cellular context, an idea strengthened by data provided by CaMKII mutations. 
Thr286Ala, a mutation that prevents autonomous activity (Fong, Taylor et al. 1989), 
disrupts the ability of CaMKII to trap CaM (Meyer, Hanson et al. 1992). Interestingly, 
this mutant is capable of substrate phosphorylation due to Ca2+/CaM activation (Fong, 
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Taylor et al. 1989) and can target to cellular compartments comparable to wild-type 
kinase (Shen, Teruel et al. 2000). However, Thr286Ala targets substrates in a weaker and 
more transient manner compared to wild-type kinase (Shen, Teruel et al. 2000, Leonard, 
Bayer et al. 2002). It appears that while autophosphorylation is a critical regulator of 
CaMKII activity, it is not necessary for substrate phosphorylation.  
 
CaMKII Inactivation  
Thr286 autophosphorylation, which is a determinant of CaMKII activity in the 
cell, can be reversed by a few ways. Firstly, high ADP can dephosphorylate CaMKII thus 
reducing autonomous activity (Kim, Hudmon et al. 2001). Second, a number of protein 
phosphatases in the cell, such as Ca2+/CaM protein phosphatase, protein phosphatase 1, 
2a and 2c, have been shown to dephosphorylate Thr286 (Fukunaga, Kobayashi et al. 
1993, Strack, Barban et al. 1997).  
 As discussed previously, phosphorylation at Thr305/306 prevents Ca2+/CaM 
binding to CaMKII thus serving as a mechanism to inactivate CaMKII. Furthermore, the 
activation of CaMKII under conditions of limited ATP and low pH induces inactivation 
of the kinase (Colbran 1993, Hudmon, Aronowski et al. 1996), a finding that is 
exacerbated under conditions of elevated temperatures (Hudmon, Aronowski et al. 1996). 
Lastly, CaMKII self-association, an activity-dependent form of aggregation involving the 
association and aggregation of CaMKII holoenzymes with one another, results in 
CaMKII inactivation. Thus, a number of different cellular events can lead to the 
inactivation of CaMKII.  
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CaMKII signaling in astrocytes 
Unlike neurons, a better understanding of the functional role of astrocytic 
CaMKII is limited by our knowledge of substrates in this type of glial cell. CaMKII has 
been implicated in a migratory phenotype in both astrocytes and glioma cells. In glioma 
cells in particular, a migratory phenotype is associated with individual glioma cells 
migrating into and invading surrounding cells. Migratory gliomas are challenging to 
treat- even following resection, as they often reconstitute a tumor rapidly (Aubert, 
Badoual et al. 2008). CaMKII interaction and phosphorylation of ClC-3, a chloride 
channel and regulator of cell volume, results in ClC-3 activation and an increase in the 
migratory phenotype in glioma cells (Cuddapah and Sontheimer 2010, Cuddapah, Turner 
et al. 2013). This finding was confirmed using inhibitors and shRNA for both CaMKII 
and ClC-3, and observing a subsequent reduction in cell migration. Furthermore, CaMKII 
has also been implicated in the regulation of glioma cell migration by direct interaction 
with ASIC1, an acid sensing cation channel (Sun, Zhao et al. 2013). In this case, binding 
has been suggested as a potential mechanism whereby CaMKII regulates ASIC1 currents, 
thus leading to migration (Sun, Zhao et al. 2013). In rat brain astrocytes, CaMKII has 
been implicated in the expression of matrix mettaloproteinase-9 expression (MMP-9), 
proteinases that are upregulated during pathological conditions of inflammation and 
disease. Furthermore, this CaMKII-dependent upregulation of MMP-9 has been shown to 
correlate with an increased migratory phenotype (Wang, Hsieh et al. 2010, Lin, Lee et al. 
2013). Thus, the action of CaMKII on numerous channels or proteins suggests it 
potentiates migration in both astrocytes and glioma cells, which may be beneficial during 
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the formation of a glial scar during pathological states or detrimental during an 
increasingly cancerous phenotype, as observed in glioblastoma.   
CaMKII has also been implicated in glutamate uptake by astrocytes. Glutamate 
application to astrocytes has been shown to result in increased calcium signaling and 
CaMKII activity (Cornell-Bell, Finkbeiner et al. 1990, Kim, Rioult et al. 1994). Our lab 
previously reported that pharmacological inhibition of CaMKII results in a reduction in 
glutamate uptake in cultured rodent cortical astrocytes (Ashpole, Chawla et al. 2013). 
Underhill et al. report that CaMKII phosphorylates DLG1, a PDZ-protein, in turn de-
stabilizing the interaction between DLG1 and EAAT2b, a splice variant of the GLT-
1/EAAT2 glutamate transporter. The functional consequence of this phosphorylation is a 
reduction in EAAT2b cell surface expression, although glutamate uptake was not 
reported (Underhill, Wheeler et al. 2015). Although advances in CaMKII regulation of 
astrocytic glutamate transporters are recent, this field is important as astrocytic glutamate 
uptake is the primary mechanism of extracellular glutamate clearance in the brain. 
Connexins are gap junctions that serve as regulators of intracellular ionic 
concentrations between cells. These hemichannels are particular important in astrocytes, 
as they connect astrocytes and allow calcium ions to pass between cells, resulting in a 
wave. CaMKII has been shown to phosphorylate connexin43, a family of connexin 
channels present on astrocytes, resulting in a decrease in the open channel probability of 
these gap junctions (Dermietzel, Traub et al. 1989, Huang, Laing et al. 2011, Xu, Kopp et 
al. 2012). Recently, astrocytic oxygen-glucose deprivation/reperfusion (OGD/R) was 
shown to decrease neurite outgrowth (Wu, Yu et al. 2015). Increased calcium signaling, 
subsequent CaMKII/CREB signaling, increased ephrin-A4 and decreased connexin43 
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expression in astrocytes as a result of OGD-R were associated with this phenotype. These 
data suggest that CaMKII regulates Connexin43 to maintain calcium flux from one cell to 
another. A loss of CaMKII activity may result in aberrant calcium signaling, as increased 
calcium dispersion may occur between unstimulated astrocytes.  
The cellular cytoskeleton can be linked to a multitude of functions, such as cell 
shape, resistance, migration, and the support of numerous other functions such as 
organelle and protein trafficking, and neurotransmitter release. These proteins can 
assemble and disassemble based on various stimuli and cellular signals. CaMKII has 
been shown to regulate a number of cytoskeletal proteins in both neurons and astrocytes 
(Fink, Bayer et al. 2003, Tsui and Malenka 2006). In astrocytes, CaMKII has been shown 
to phosphorylate the cytoskeletal protein, vimentin and result in the disassembly of 
vimentin filaments (Inagaki, Nishizawa et al. 2000, Oguri, Inoko et al. 2006), which can 
impact cytoskeletal functions such as cell structure and migration. Furthermore, CaMKII 
has been implicated in the phosphorylation of GFAP, a cytoskeletal protein marker of 
mature and reactive astrocytes (Leal, Goncalves et al. 1997, Frizzo, Tramontina et al. 
2004), although the functional relevance of this phosphorylation is not fully understood. 
As described previously, astrocytic CaMKII phosphorylation of a scaffolding protein 
DLG1 resulted in altered membrane trafficking of a splice variant of the glutamate 
transporter EAAT2, thus decreasing glutamate uptake (Underhill, Wheeler et al. 2015). 
Thus, scaffolding proteins are capable of regulating a number of functions, and CaMKII 
regulation of these proteins can be essential to maintain physiological function. 
In sum, it appears that calcium signaling is crucial for a variety of functions in the 
astrocyte. Our understanding of the molecular mechanisms underlying glutamate uptake, 
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a key role performed by astrocytes, is limited. It is known that EAAT1 and EAAT2 are 
the primary molecular players governing an astrocytes’ ability to clear extracellular 
glutamate. We chose to focus on astrocytic glutamate transporter regulation by a key 
calcium-regulated enzyme, CaMKII. Our studies suggest the involvement of a calcium-
dependent mechanism in maintaining control of extracellular glutamate in the central 
nervous system.   
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RESEARCH GOALS 
Ultimately, a better understanding of the regulation underlying astrocytic 
glutamate uptake improves our grasp of a key functional component of astrocyte 
physiology. I had previously established a link between a CaMKII activity and glutamate 
uptake in an astrocyte culture model. The purpose of this dissertation was to focus on 
which isoform of glutamate transporter was regulated by CaMKII, and addressing 
whether phosphorylation served as a potential mechanism of regulation. 
 In order to address this, I will express EAAT1 and EAAT2 in a heterologous 
system in order to delineate isoform-specific regulation. Furthermore, I will test the role 
of different CaMKII states in this regulation. Lastly, I will test the role of direct 
phosphorylation being associated with functional changes observed upon altering 
CaMKII activity. These experiments will elucidate a regulatory mechanism whereby 
CaMKII controls glutamate uptake via either one of both astrocytic glutamate 
transporters, and expand our understanding of CaMKII substrates and function in 
astrocytes.  
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MATERIALS AND METHODS 
Materials  
Glutamic acid, glycine, polyethylenimine (PEI) and DL-threo-β-benzyoxyaspartate 
(TBOA) were purchased from Sigma. 2-Amino-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-
7-(naphthalen-1-yl)-5-oxo-4H-chromene-3-carbonitrile (UCPH-101) was obtained from 
Abcam. Autocamtide-2 (KKALRRQETVDAL), Tat-CN21 
(YGRKKRRQRRRKRPPKLGQIGRSKRVVIEDDR) and tat-CN21Ala 
(YGRKKRRQRRRKAPAKAAQAAASKRVVIEDDR) were synthesized by Biopeptide 
Co. Inc (San Diego, CA). Lipofectamine-2000 was purchased from Invitrogen. Protease 
inhibitors, KN-92 and KN-93 were purchased from EMD Millipore. Radiolabeled [3H]-
glutamate was obtained from American Radiolabeled Chemicals and [γ-32]-ATP was 
obtained from Perkin-Elmer.  
 
cDNA constructs 
cDNA for human EAAT1 and EAAT2 (obtained from Addgene in a pCMV5 backbone; a 
generous gift from Susan Amara at the National Institute of Mental Health) were 
subcloned into Creator-based acceptor vectors (generous gift from Dr Clark Wells at 
Indiana University) for mammalian expression with the N-terminal tag mCherry and a 
gene for ampicillin resistance as previously described (Adler, Johnson et al. 2013). For 
GST-fusion protein experiments, N- and C-termini of EAAT1 and EAAT2 were sub-
cloned into PGEX vectors containing a GST tag. The cDNA for human δCaMKII was 
described previously (Ashpole, Herren et al. 2012). It was subcloned into a Creator-based 
vector with a YFP tag.  
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Site-directed mutagenesis 
Site-directed mutagenesis (Agilent Technologies) was used to introduce point mutations 
into the cDNA for CaMKII or EAAT1. Briefly, PCR reaction mix was made according to 
the manufacturer’s instructions. An overnight PCR reaction was performed using the 
following settings: Initial denaturation (95°C, 2 mins), 18 cycles of denaturation (95°C, 1 
min), annealing (60°C, 1 min), and extension (68°C, 2.5 min/Kb), followed by a 7 minute 
elongation step at 68°C. Dpn1 was added to the PCR product for 2 hours at 37°C to 
digest methylated DNA. DNA was then transformed into XL-10 Gold Ultracompetent 
cells. Primers used for site-directed mutagenesis are annotated in Table 2. Double 
mutations were carried out sequentially. All mutations were verified by gene sequencing 
(Eurofins MWG Operon).  
 
Cell lines 
A172s, a glioblastoma cell line, and human embryonic kidney (HEK293Ts) were 
obtained from the American Type Culture Collection and cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 4.5g/L glucose, 29.2 µg/mL L-glutamine, 
10% heat inactivated fetal bovine serum, penicillin (10 units/mL), and streptomycin (10 
µg/mL) at 37°C in 5% CO2 as previously described (Hudmon, Lebel et al. 2005, Ashpole, 
Herren et al. 2012). Cells were washed at confluency with phosphate-buffered saline at 
room temperature, and passaged using 0.05% trypsin (Invitrogen).   
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cDNA Mutation Primer Sequence (5' to 3') 
δCaMKII Thr287Asp atttcttcaagcagtctacatcctcctgtctgtgcatcatgg 
δCaMKII Thr287Asp ccatgatgcacagacaggaggatgtagactgcttgaagaaat 
δCaMKII Thr287Val atttcttcaagcagtctacaacctcctgtctgtgcatcatgg 
δCaMKII Thr287Val ccatgatgcacagacaggaggttgtagactgcttgaagaaat 
δCaMKII Asp136Asn attctcaggcttcaggttcctgtgaactatgccat 
δCaMKII Asp136Asn atggcatagttcacaggaacctgaagcctgagaat 
   
EAAT1 Thr26Ala ttcttggccaaaagtgcgcgtttacggactccc 
EAAT1 Thr26Ala gggagtccgtaaacgcgcacttttggccaagaa 
EAAT1 Thr26Asp cactttcttcttggccaaaagatcgcgtttacggactccctgctg 
EAAT1 Thr26Asp cagcagggagtccgtaaacgcgatcttttggccaagaagaaagtg 
EAAT1 Thr37Ala gtaacttttaacatcctcctttgcaatgttctgcactttcttcttgg 
EAAT1 Thr37Ala ccaagaagaaagtgcagaacattgcaaaggaggatgttaaaagttac 
EAAT1 Thr37Asp cacacttttggccaagaagaaagtgcagaacattgataaggaggatgttaaaagtta 
EAAT1 Thr37Asp taacttttaacatcctccttatcaatgttctgcactttcttcttggccaaaagtgtg 
 
  
Table 2: Primers used for site-directed mutagenesis 
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Astrocyte cultures 
Cortical astrocyte cultures were derived from postnatal day 1-2 Sprague-Dawley rat pups 
as per approved IACUC guidelines using methods previously established (McCarthy and 
de Vellis 1980, Ashpole, Chawla et al. 2013). Briefly, rodent cortices were removed from 
the cranium following rapid decapitation, and the meninges and blood vessels were 
cleaned off. Tissue was digested using papain, triturated, and re-suspended in growth 
media (DMEM containing 2% NuSerum, 4.5g/L glucose, 29.2 µg/mL L-glutamine, NS-
21 supplement, 10 units/mL penicillin, and 10 µg/mL streptomycin) at a density of 2.5 
million cells/mL and seeded on poly-D-lysine (PDL, 50 µg/mL) coated 10 cm dishes. 
Half the media was replaced every 3-4 days with fresh growth media. Cells were split at 
confluency (~7-8 days in vitro) using 0.1% trypsin, shaking the dishes to remove 
oligodendrocytes, and seeded on PDL-coated 12 mm coverslips for 
immunocytochemistry or on PDL-coated 35 mm dishes for [3H]-glutamate uptake assays. 
Cultures were maintained at 37°C in 5% CO2. 
 
Transient transfections 
A172s and HEK293Ts were transfected at 50-60% confluency with 2.5 µg cDNA per 35 
mm dish. Transfection reagents Lipofectamine-2000 (10uL per 35 mm dish) and PEI 
(2mg/mL) were utilized as the transfection reagents for A172s and HEK293Ts 
respectively, in serum-free Opti Modified Eagle’s Medium (OptiMEM). cDNA was 
mixed with transfection reagents in 100 µl OptiMEM, and incubated at room temperature 
for 10 (PEI) or 30 (Lipofectamine-2000) minutes, and then directly added to cells in 
DMEM. Assays were performed 16-24h later, when cells were 80-100% confluent.  
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Immunocytochemistry of astrocyte cultures 
Immunocytochemistry was performed as described briefly (Ashpole and Hudmon 2011, 
Ashpole, Herren et al. 2012). Astrocytes seeded onto 12 mm coverslips were fixed for 15 
minutes using 3-4% paraformaldehyde, permeabilized for 15 minutes using 0.25% Triton 
X-100 (TX-100), and blocked using blocking buffer (5% goat serum, 0.25% TX-100, 
0.3M glycine) for 2 hours at room temperature. Coverslips were washed twice with PBS 
between each step. Next, the cultures were incubated in polyclonal rabbit anti-GFAP 
(1:1000) overnight at 4°C, followed by incubation in goat anti-rabbit Alexa680 (1:5000) 
for an hour at room temperature. The coverslips were then washed in PBS and mounted 
in Prolong Gold Antifade mounting media containing DAPI (Molecular Probes), dried 
overnight, and imaged the next day.  
 
Immunocytochemistry of fetal astrocyte cultures 
Immunocytochemistry was performed on fetal astrocytes seeded onto collagen-coated 12 
mm coverslips as described above. Specifically, the cultures were incubated in chicken 
anti-GFAP (1:500), mouse anti-MAP2 (1:1000), mouse anti-OX42 (1:1000), and rabbit 
anti-Olig2 (1:1000) primary antibodies overnight at 4°C, followed by incubation in goat 
anti-mouse Alexa680 (1:5000) or goat anti-rabbit Texas red for an hour at room 
temperature. The coverslips were then washed in PBS and mounted in Prolong Gold 
Antifade mounting media containing DAPI (Molecular Probes), dried overnight, and 
imaged the next day.  
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Fluorescence Imaging 
A Zeiss fluorescent microscope was utilized to monitor fluorescence intensity. Cells were 
imaged using the Texas red, FITC, or DAPI filters using Zeiss Axio Observer Z1 and 
processed with Axiovision 4 (10 or 20x magnification). All images were taken after cells 
had been transfected for 16-24h, in order to represent transfection efficiency as close to 
[3H] uptake measurements as possible.  
 
CaMKII [γ-32]-ATP Activity Assays 
HEK293T cultures were washed in cold PBS twice, and lysed in 20 mM Tris pH 7.4, 200 
mM NaCl, 0.1 mM EDTA, using a homemade protease inhibitor cocktail (1 mM AEBSF, 
300 nM Aprotinin, 2 µM E-64, 2 µM Leupeptin) as described previously (Ashpole, 
Chawla et al. 2013). The lysate was sonicated briefly, vortexed, and incubated with 0.5% 
Triton-X 100 for 5-10 minutes on ice. Total CaMKII activity was measured by incubating 
the lysate with 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 100 µM ATP, 2 
mM CaCl2, 5 µM CaM, 50 µM AC-2 (KKALRRQETVDAL) and [γ-32]ATP (3 µCi per 
reaction) for 5 minutes at 30°C. Autonomous CaMKII activity (Ca2+/CaM-independent 
activity) was measured by incubating the lysate under similar conditions except 5 mM 
EGTA replaced Ca2+/CaM. The radiolabeled reaction was spotted onto Whatman grade 
P81 ion exchange cellulose filter paper, and washed three times in 75 mM phosphoric 
acid to remove unbound [γ-32]-ATP. To control for non-specific AC-2 phosphorylation in 
the lysate, reactions were incubated in the absence of AC-2. The linear range of the 
phosphorylation reaction extends >10 mins. A DC protein assay kit (Bio-Rad) was used 
to measure protein levels in the lysate. In brief, serial dilutions of the standard bovine 
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serum albumin were made in order to generate a standard curve. Samples were then 
diluted in buffers from the kit as per manufacturer’s instructions, and concentrations were 
calculated based on the known concentrations of the standard. CaMKII activity was 
normalized to total protein to account for variability in cell density or lysis.  
 
[3H]-Glutamate Uptake Assays 
HEK293Ts were transfected as described above with either vector control mCherry only, 
EAAT1 or EAAT2. Cultures were pre-treated with pharmacological antagonists 10 µM 
UCPH-101 (EAAT1 inhibitor) and 10 µM TBOA (EAAT2 inhibitor) for 20 min at 37°C 
to confirm isoform-specific glutamate transporter measurements. For CaMKII inhibition 
experiments, cultures were pre-treated with 5 µM KN-93 and tat-CN21 (CaMKII 
inhibitors), or 5 µM KN-92 and 5 µM tat-CN21Ala (CaMKII inhibitor controls) for 20 
minutes at 37°C. Rat physiological saline (138 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 
1.06 mM MgCl2, 12.4 mM HEPES, pH 7.4, 5.6 mM glucose; final pH adjusted to 7.3) 
containing 0.1 µCi/ml [3H]-glutamate and 100 µM unlabeled glutamate was then applied 
to HEK293T cells for 20 min at 37°C. If an inhibitor or inhibitor control was previously 
applied to the cultures, it was also added during glutamate treatment, keeping the 
concentration consistent. The cultures were then washed in cold PBS twice, lysed in lysis 
buffer (above) containing 1%Triton X-100, vortexed briefly and incubated for 5 min on 
ice. Next, lysates were diluted in 8 ml RadSafe liquid scintillation cocktail (Beckman 
Coulter) and [3H] was quantified using a scintillation counter. The linear range of the 
glutamate uptake reaction extends ≤1 hour. A DC protein assay was performed as 
described above, and uptake was normalized to total protein. 
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In Vitro SPOTs Phosphorylation Assay 
15-amino acid long peptides spanning the intracellular regions of EAAT1 and EAAT2 (1-
15, 2-16, 3-17 etc.) were synthesized onto β-alanine derivatized cellulose membranes 
using the SPOTS synthesis method as described previously (Adler, Johnson et al. 2013). 
Following synthesis, the membrane was de-protected twice with a solution of 
trifluoroacetic acid containing 5% phenol and 2% triisopropylsilane. Next, the membrane 
was blocked with 5% BSA in 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, and 
0.02% NP-40 for 30 minutes followed by three washes in 100 mM Tris-HCl pH 7.4.  A 
pre-reaction was performed in the presence of 20 mM HEPES pH 7.4, 100 mM NaCl, 10 
mM MgCl2, 0.5 mM CaCl2, 5 µM CaM, 500 µM cold ATP and 500 nM recombinant 
purified human δCaMKII for 10 minutes on ice to autophosphorylate δCaMKII at T287 
as described previously (Ashpole, Herren et al. 2012). Membranes were subjected to a 
kinase phosphorylation assay in the presence of 50 mM HEPES pH 7.4, 100 mM NaCl, 
10 mM MgCl2, 0.2 mM CaCl2, 1 µM CaM, 0.2 mg/ml BSA, 1 mM DTT, 100 µM cold 
ATP, 120 µCi/ml [γ-32]-ATP, and 5-10 nM δCaMKII.  The reactions were incubated at 
room temperature for 4 minutes, terminated with three washes (100mM sodium 
phosphate pH 7.0, 1 M NaCl, 10 mM EDTA) and dried as described previously (Ashpole, 
Herren et al. 2012).  The extent of radioactive phosphate incorporation was quantified 
using a Fujifilm phosphoimager and expressed as photostimulated luminescence 
(PSL/mm2) for a 1.5 mm x 1.5 mm circle centered on each spot.  V3.1 of the MultiGauge 
software was used to detect and quantify phosphorylation of each peptide spot.  
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Ionomycin activation of CaMKII 
HEK293T cells were transfected with δCaMKII cDNA at ~60-70% confluency. After 16-
24 hours, δCaMKII was activated using 10µM ionomycin for 1 min and 20 mins, using 
methanol as a vehicle control. Cells were then lysed in lysis buffer (described above). [γ-
32] assays were performed to measure phosphate incorporation into the CaMKII substrate 
AC-2. [3H]-glutamate uptake assays were carried out to measure the effect of increasing 
calcium signaling on glutamate uptake.  
 
Co-immunoprecipitation 
3x FLAG-tagged versions of EAAT1 and EAAT2 were co-transfected into HEK293T 
cells with δCaMKII at ~60-70% confluency. After 16-24 hours, δCaMKII was activated 
using 10µM ionomycin for 20 mins, following which cells were lysed using lysis buffer 
(described above), spun down at 200 X g for 10 minutes and the pellet was homogenized 
using lysis buffer containing 1% TX-100, protease and phosphatase inhibitors. 20µL of 
each sample was collected and labeled ‘lysate’ to serve as a positive control for 
transfection. Lysate was then exposed to either mouse IgG or mouse FLAG antibody for 
2 hours at 4°C. After this incubation, washed Protein G agarose beads were added to each 
sample for 1 hour at 4°C. Samples were then rinsed three times using lysis buffer, and a 
Western blot was run to detect the FLAG-tagged protein and CaMKII.   
 
GST-fusion protein phosphorylation 
GST-tagged intracellular N- and C- termini of human EAAT1 and EAAT2, EAAT1 N 
terminii mutants, GluR1 and a GST vector control were expressed in BL-21 Escherichia 
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coli cells overnight at 16°C using 0.2 mM isopropyl 1-thio-β-D-galactopyranoside to 
induce protein expression. Cells were centrifuged at 200 X g for 10 minutes, re-
suspended in lysis buffer (described above) and passed through a microfluidizer three 
times to lyse cells. A supernatant was collected after centrifugation (8,000 X g for 10 
mins) and snap-frozen for single use aliquots. GST-fusion proteins were bound to 
glutathione agarose in binding buffer (20 mM Tris pH 7.4, 200 mM NaCl, 1 mM EDTA, 
0.1% Tween-20 containing protease inhibitor) tumbling for 1.5 hours at 4°C. The beads 
were then washed three times in binding buffer to remove any unbound lysate. A pre-
reaction was performed as described above to activate and autophosphorylate human 
δCaMKII. GST-bound fusion proteins were then phosphorylated on the glutathione beads 
with 100 nM δCaMKII in reaction mix containing 20 mM HEPES pH 7.4, 100 mM 
NaCl, 10 mM MgCl2, 0.25 mM CaCl2, 5 µM CaM, 10 µM cold ATP, and 60 µCi/ml [γ-
32P]-ATP for 30 mins at room temperature. The reaction was quenched with three 500 
mM EDTA washes, followed by addition of LDS sample loading buffer and β-
mercaptoethanol to denature proteins at 80°C. Overnight Coomassie staining of the gel 
allowed for visualization of GST-fusions and protein quantification using Image J 
densitometry (NIH). CaMKII phosphorylation of GST fusion proteins was detected upon 
transfer of radioactive signal [γ-32P] onto a screen, using a phosphoimager (Fujifilm) for 
visualization and quantified using V3.1 of the MultiGauge software as described above.  
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Statistical Analysis 
SigmaPlot version 12.5 was used to perform statistical analysis. A one-way ANOVA 
followed by a post hoc Dunnett’s test was used to compare differences between the 
means of each group. A p value of <0.05 was considered statistically significant.  
  
	 70 
RESULTS 
Immunocytochemical characterization of rodent cultured cortical astrocytes  
 In order to assess CaMKII regulation of glutamate uptake, we generated 
cortical astrocyte cultures from postnatal rodents using a well-established protocol 
(McCarthy and de Vellis 1980). Briefly, we harvested the brain from postnatal rat pups 
(P1-P3) and plated the cells following mechanical and enzymatic processing of the tissue. 
Once the cells reached confluence (8-10 days), we mechanically dislodged contaminating 
cells (primarily oligodendrocytes and neurons) using forceful shaking and split the 
cultures to enrich for astrocytes. Although this protocol to harvest and culture astrocytes 
is well accepted in the field, we verified cellular content by immunostaining for specific 
cellular markers to identify neurons (MAP2), microglia (OX42), and astrocytes (GFAP 
and vimentin). We used the nuclear stain Hoechst, a dye that binds double-stranded 
DNA, in order to confirm nuclear integrity and to determine total cell numbers for 
characterizing astrocyte contamination by other glia and neurons. We observed that 93.9 
+/- 10.8 % (n = 6) of these cells were GFAP positive (Figure 4A) and 78.9 +/- 21.2% (n 
= 6) were vimentin positive (Figure 4B), both intermediate filament proteins expressed 
in reactive cultured astrocytes. Furthermore, we observed that only 2.3 +/- 3.9% (n = 6) 
were OX42 positive, suggesting that there is little to no contamination by microglial 
cells. The microtubule associated neuronal protein, MAP-2, was not detected in these 
cultures. Overall, these findings suggest our cultures are predominantly astrocytic (~80-
94% based on the protein marker being used), with minimal if any contamination from 
microglia and neurons. This characterization was published in the “Journal of Biological 
Chemistry. Ashpole N, Chawla A, Martin M, Brustovetsky T, Brustovetsky N, Hudmon 
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A. Loss of Calcium/Calmodulin-dependent protein kinase II activity in cortical astrocytes 
decreases glutamate uptake and induces neurotoxic release of ATP. Journal of Biological 
Chemistry. 2013; Vol 288:14599-14611. © the American Society for Biochemistry and 
Molecular Biology”. 
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Figure 4: Characterization of rodent cortical astrocytes. Shown are representative 
images of a field of astrocytes immunostained with A: GFAP (green), OX42 (red) and 
Hoechst (blue). B: Vimentin (red) and pan CaMKII (green). The scale bar represents 20 
µM length. C: Average [32P] incorporation into the CaMKII peptide substrate AC-2 for 
Ca2+/CaM-stimulated (total) and Ca2+/CaM-independent (autonomous) activity within 
astrocyte lysates. D: Average [32P] incorporation into the CaMKII peptide substrate AC-2 
for Ca2+/CaM-stimulated activity within astrocyte lysates upon treatment with 5 µM tat-
CN21 and tat-CN21Ala. Asterisk indicates significant difference compared to control (*, 
p< 0.05, one-way ANOVA, post-hoc Dunnett's test). 
“Panels A and B were originally published in the Journal of Biological Chemistry. 
Ashpole N, Chawla A, Martin M, Brustovetsky T, Brustovetsky N, Hudmon A. Loss of 
Calcium/Calmodulin-dependent protein kinase II activity in cortical astrocytes decreases 
glutamate uptake and induces neurotoxic release of ATP. Journal of Biological Chemistry. 
2013; Vol 288:14599-14611. © the American Society for Biochemistry and Molecular 
Biology." 
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Characterization of CaMKII in rodent cultured cortical astrocytes 
 Next, we tested our cultures for the presence/activity of CaMKII using a 
number of different methodologies. Immunocytochemical analyses detect 93.0 +/- 9.8% 
of our cultured astrocytes stained positive for CaMKII using a pan-CaMKII antibody, 
suggesting CaMKII is present in almost all the cells in our culture system (Figure 4B). 
Furthermore, the CaMKII protein appears to localize in both a nuclear and cytoplasmic 
context. It is important to note that CaMKII does not appear to be sequestered in 
intracellular compartments that may be hard to access using our pharmacological tools, 
based on these data. Next, we measured CaMKII catalytic activity in our astrocyte 
cultures. Our purpose for doing so was two-fold: one, we wanted to confirm our 
immunocytochemical findings that detected CaMKII expression in our astrocytic 
cultures, and two, we wanted to determine the extent of activated or autonomous kinase 
present in our cultures. In order to quantify this, we measured Ca2+/CaM-dependent (total 
activity) and Ca2+/CaM-independent activity (autonomous activity) as a function of [γ-
32P] incorporation into AC-2, a highly selective peptide substrate of CaMKII derived 
from the Thr-286 autophosphorylation site of the alpha subunit of CaMKII. Lysate 
activity was measured in the absence of AC-2 to control for non-specific substrate 
phosphorylation (<5% of total activity). We observed that 22.4 ± 5.28% of CaMKII 
activity is autonomous as a percentage of total CaMKII activity (Figure 4C). This 
autonomous kinase activity represents the pool of activated CaMKII or ‘basal’ CaMKII 
present in the astrocyte, which likely reflects prior CaMKII activation by canonical 
Ca2+/CaM, however, this activity can also be generated by other post-translational 
modifications (Mattiazzi, Bassani et al. 2015), including glycosylation (Erickson, Pereira 
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et al. 2013), nitrosylation (Coultrap and Bayer 2014) and oxidation (Erickson, Joiner et 
al. 2008, Erickson, He et al. 2011). The function of this autonomous CaMKII activity is 
believed to generate a basal level of CaMKII activity relevant for constitutive 
physiological CaMKII signaling. Next, we tested the effect of the high affinity peptide 
inhibitor, tat-CN21 in our astrocytes cultures. CN21 is a 21 amino acid long peptide 
inhibitor of CaMKII generated from the naturally occurring inhibitor protein, CaMKIIN 
(Vest, O'Leary et al. 2010, Ashpole and Hudmon 2011). For these experiments, it was 
conjugated to the cell-permeable sequence, tat (YGRKKRRQRR). We did this in order to 
confirm the specificity of our assay (although carrying out the experiment in the absence 
of AC-2 tests the same) and that we could, in fact, reduce CaMKII activity. We observed 
a 56 ± 20% reduction in total CaMKII activity with tat-CN21 application that was 
significant, while the inactive control, tat-CN21Ala reduced total CaMKII activity by 12 
± 17% that was non-significant (Figure 4D). Overall, our findings suggest rodent 
cultured cortical astrocytes express CaMKII, a fraction of which exists in the activated or 
autonomous form.  
 
Pharmacological inhibition of CaMKII in rodent cultured cortical astrocytes 
diminishes [3H]-glutamate uptake 
 Given the correlation between CaMKII inactivation and neuronal death, and 
increased extracellular glutamate/dysregulation in glutamate uptake with an increase in 
neuronal death, we asked the question: Does CaMKII regulate glutamate uptake? We first 
confirmed the efficacy of our experimental paradigm. We measured [3H]-glutamate 
uptake in the presence of a non-selective glutamate transporter inhibitor, TBOA, for 20 
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minutes at a concentration that targets all tested EAATs (100µM). Uptake was measured 
using a liquid scintillation counter, and counts were normalized to protein concentration 
in order to reduce variability between samples. We found that >85% of observable [3H]-
glutamate uptake is inhibited by 100uM TBOA, confirming that our [3H] measurement is 
primarily mediated via excitatory amino acid transporters (Figure 5). We employed two 
well-established CaMKII inhibitors: KN-93, a small molecule inhibitor that competes 
with Ca2+/CaM but not ATP for CaMKII activation (Sumi, Kiuchi et al. 1991, Pellicena 
and Schulman 2014), and tat-CN21, a membrane permeable CaMKII inhibitor that 
inhibits both stimulated and autonomous CaMKII activity (Buard, Coultrap et al. 2010). 
Inactive versions/controls for the respective inhibitors (KN-92 and tat-CN21Ala) were 
used to verify the specificity of the active compounds and control for off-target effects. 
We find that application of both KN-93 and tat-CN21 produce a significant reduction in 
uptake (45 ± 4% and 46 ± 5% respectively), while their respective inactive controls do 
not alter [3H]-glutamate uptake (Figure 5). These data suggest CaMKII regulates 
astrocytic glutamate transport. Cortical astrocytes, however, express the glutamate 
transporters GLAST/EAAT1 and GLT-1/EAAT2 (Kondo, Hashimoto et al. 1995, 
Rothstein, Dykes-Hoberg et al. 1996) and thus do not represent a good model system to 
parse out differences in transporter regulation. In order to explore the identity and 
mechanisms underlying glutamate transporter regulation by CaMKII in a tightly 
controlled manner, we moved to a heterologous expression system previously used to 
study glutamate transporter function. The focus of my dissertation is to address the 
specificity and mechanism of CaMKII regulation of the astrocytic glutamate transporters.  
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Thus, the specific aims of my study were: 
1. To determine the contribution of EAAT1 and/or EAAT2 in the regulation of 
astrocytic glutamate uptake by CaMKII 
2. To determine the role of CaMKII phosphorylation in astrocytic glutamate 
transporter(s) activity 
 
 I hypothesize that CaMKII modulation of either EAAT1 and/or EAAT2 
contributes to the phenotype of diminished glutamate uptake upon loss of CaMKII 
signaling in astrocytes. Furthermore, as CaMKII is a serine/threonine kinase, we 
hypothesized that CaMKII modulated the activity of the glutamate transporters via 
phosphorylation.  
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Figure 5: Decreased glutamate uptake in astrocytes with CaMKII inhibition. 
Average [3H]glutamate uptake (n = 3, ±S.D.) in astrocytes pretreated with either 0.2% 
DMSO, 100 µM DL-threo-β-Benzyloxyaspartic acid (TBOA), 10 µM tat-CN21, 10 µM 
tat-CN21Ala, 1 µM KN-93, or 1 µM KN-92 for 20 min. The asterisk indicates 
significant difference compared to control (*, p < 0.05, one-way ANOVA, post-hoc 
Dunnett's test). 
"This research was originally published in the Journal of Biological Chemistry. Ashpole 
N, Chawla A, Martin M, Brustovetsky T, Brustovetsky N, Hudmon A. Loss of 
Calcium/Calmodulin-dependent protein kinase II activity in cortical astrocytes 
decreases glutamate uptake and induces neurotoxic release of ATP. Journal of 
Biological Chemistry. 2013; Vol 288:24599-14611. © the American Society for 
Biochemistry and Molecular Biology." 
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Characterization of HEK293Ts as a model to study CaMKII regulation of 
glutamate uptake by astrocytic excitatory amino acid transporters 
 Human-embryonic-kidney cell lines (HEK293T) have been previously used as 
a model system to study glutamate uptake (Dunlop, Lou et al. 1999, Berry, Hayes et al. 
2005, Peacey, Miller et al. 2009). However, before studying our transfected transporters 
we wanted to first characterize endogenous glutamate transporter activity in the 
HEK293T cell background. Because we observed a measurable level of glutamate uptake 
under our experimental conditions, we attempted to discern whether this uptake had a 
classical pharmacological phenotype using the EAAT1 inhibitor, UCPH-101 (Erichsen, 
Huynh et al. 2010) and EAAT2 inhibitor, TBOA. While TBOA is not considered a 
selective EAAT inhibitor, it is relatively specific for EAAT2 at low micromolar 
concentrations (Shimamoto, Sakai et al. 2004). We observed that 63±3% glutamate 
uptake is reduced by the addition of 10 µM UCPH-101 and a 30±1% reduction in 
glutamate uptake occurs upon the addition of 10 µM TBOA in untransfected HEK293T 
cells (Figure 6A). While these findings suggest that a portion of endogenous [3H]-
glutamate uptake in naïve HEK293T cells may be due to EAAT1 and EAAT2 activity, it 
is likely this glutamate uptake is due to EAAT3 (Toki, Namikawa et al. 1998), a subtype 
of glutamate transporter predominantly localized to neurons and kidney cells (Kanai and 
Hediger 1992). Additional studies are required to address this finding in further detail. 
For the purpose of our studies, however, both UCPH-101 and TBOA serve as positive 
controls.  
 We next wanted to study the consequence of pharmacological inhibition of 
CaMKII on glutamate uptake by untansfected HEK293T cells. Application of the 
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CaMKII inhibitors and inhibitor controls previously described (KN-92, KN-93, tat-
CN21Ala, and tat-CN21) to untransfected HEK293T cells did not produce a significant 
reduction in [3H]-glutamate uptake (Figure 6B). The findings suggest that neither the 
inhibitors nor the inhibitor controls have an effect on endogenous glutamate transporters 
in this cell line, allowing us to utilize these pharmacological agents for our assays. It is 
important to note that the overall [3H]-glutamate uptake generated by HEK293T cells is 
‘low’ compared to heterologous expression of EAAT1 and EAAT2 (depicted in Figure 
7D). Furthermore, as the majority of endogenous [3H]-glutamate uptake has been 
attributed to the glutamate transporter EAAT3, heterologous expression of EAAT1 and 
EAAT2 can allow us to specifically isolate these transporters in our model system. 
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Figure 6: Characterization of HEK293T cells. A: Average [3H]-glutamate uptake (n= 
3, ±S.D.) in HEK293T cells pre-treated with UCPH-101 (10 µM) and TBOA (10 µM). 
B: Average [3H]-glutamate uptake (n= 3, ±S.D.) in HEK293T cells pre-treated with KN-
92 (5 µM), KN-93 (5 µM), tat-CN21 Ala (5 µM) and tat-CN21 (5 µM). Asterisk 
indicates significant difference compared to control (*,p< 0.05, one-way ANOVA, post-
hoc Dunnett's test). 
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Characterization of EAAT1/2 transfected HEK293Ts as a model to study CaMKII 
regulation of glutamate uptake 
 We next expressed EAAT1 and EAAT2 individually using an expression 
vector containing a mCherry-tag. The fluorescent reporter is fused N-terminus of the 
transporter where it functions as a surrogate of transporter expression. Using this 
heterologous expression system, we first quantified the percentage of cells expressing 
EAAT1 or EAAT2 by measuring mCherry fluorescence. As a function of mCherry 
fluorescence, EAAT1 and EAAT2 were expressed in 46% ± 7 and 43% ± 9 cells 
respectively, comparable to the mCherry vector control (50% ± 5, Figures 7A and 7B). 
Functionally, the transfected transporters displayed similar levels of activity 24 hours 
post-transfection. Heterologous expression of EAAT1 and EAAT2 produced a 3.08 ± 
0.14 fold and 3.31 ± 0.32 fold increase in [3H]-glutamate uptake respectively compared to 
untransfected HEK293T cells (Figure 7C). These findings were consistent with a 
previous study reporting a 3-4 fold increase in glutamate uptake using similar 
concentrations of radiolabeled and unlabeled glutamate (Dunlop, Lou et al. 1999). Using 
an EAAT1 inhibitor, UCPH-101 (Erichsen, Huynh et al. 2010) and EAAT2 inhibitor, 
TBOA (Shimamoto, Sakai et al. 2004), we were able to knock down glutamate uptake 
generated by transfected EAAT1 and 2 respectively (Figure 7C), suggesting that the 3H 
measurements are likely via EAAT activity. However, a possible interpretation of these 
data is that transfection alone may result in alterations (in particular an increase) in [3H]-
glutamate uptake. Thus, we tested whether the control vector for EAAT1 and EAAT2 
altered [3H]-glutamate uptake. We find that the mCherry tag-containing control vector (1 
± 0.14 fold increase) did not alter [3H]-glutamate uptake when compared to control 
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conditions (Figure 7D). These data confirm that EAAT1 and EAAT2 transfection 
enhances [3H]-glutamate uptake in HEK293T cells as expected.  
 In experiments described thus far (Figures 6, 7C and D), we measured [3H]-
glutamate uptake at a time point of 20 mins based on glutamate uptake data generated in 
astrocytes (Figure 5). However, in order to determine linearity of the glutamate uptake 
reaction in HEK293T cells, we carried out a time course.  For this assay, each dish was 
transfected with EAAT1 or EAAT2, [3H]-labeled and unlabeled glutamate were added to 
HEK293T cells for varying amounts of time (ranging between 10 mins and 2 hours). We 
find that our [3H]-glutamate uptake measurements were linear for up to 1 hour, after 
which uptake started plateauing (Figure 7E). A number of interpretations can be made 
from these data. First, as the reaction is linear from time points 10 mins up to1 hour, it is 
likely that glutamate is not used up during this duration. Second, the conditions of the 
uptake assay become saturating between 1-2 hours, observed by glutamate uptake values 
remaining consistent and even slightly decreasing in both EAAT1 and EAAT2 
transfected cells from 1-2 hours. The decrease and/or saturation in uptake could be due to 
increased levels of intracellular glutamate building up that ultimately cause the 
transporters to reverse, leading to extrusion of glutamate that has been taken up. Keeping 
this in mind, for the rest of our assays, we chose to study [3H]-glutamate uptake at a time 
point of 20 minutes. Our data suggests that the dynamic range for [3H]-glutamate uptake 
generated by EAAT2 versus EAAT1 is slightly higher although we normalized the time 
points to their respective transporter glutamate measurements at 10 minutes. While this is 
suggestive of faster turnover by the EAAT2 transporter compared to EAAT1, the reason 
behind this phenomenon is unclear and we chose not to explore this in further detail. In 
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summary, HEK293T cells represent a viable heterologous expression system to study 
CaMKII regulation of glutamate uptake mediated by EAAT1 and EAAT2.  
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Figure 7: Heterologous expression of human glutamate transporters EAAT1 and 
EAAT2 in HEK293T cells. A: shown is a representative image of EAAT1 transfected 
HEK293T cells. The image is viewed under red fluorescent light (RFP, left), and the 
corresponding RFP/white light merged image is shown on the right. B: shown is a 
representative image of EAAT2 transfected HEK293T cells. The image is viewed under 
red fluorescent light (RFP, left), and the corresponding RFP/white light merged image is 
shown on the right. The scale bar corresponds to 100 µM in all panels. C: Average [3H]-
glutamate uptake in EAAT1 and EAAT2 transfected cells (n=3, ± S.D) normalized to 
untransfected HEK293T cells. Inhibitors 10 µM UCPH-101 and 10 µM TBOA were added 
to EAAT1 and EAAT2 transfected cells respectively for 20 minutes prior to a 20 minute 
[3H]-glutamate uptake measurement protocol. D: Average [3H]-glutamate uptake in 
mCherry vector control, EAAT1 and EAAT2 transfected cells (n=3, ± S.D) normalized to 
untransfected HEK293T cells. E: Time course of [3H]-glutamate uptake in EAAT1 and 
EAAT2 transfected HEK293T cells. [3H]-glutamate uptake was normalized to the 
measurement at the 10 minute time point. 
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CaMKII inhibition results in a reduction in EAAT1 but not EAAT2-mediated [3H]-
glutamate uptake 
 We have previously shown that pharmacological inhibition of CaMKII has no 
effect on naïve/untransfected HEK cells (Figure 6B).  These data suggest that any 
changes observed under our experimental paradigm will not be a result of altered 
endogenous transporter activity, but rather the transfected transporter. Thus, while ¼ of 
the uptake signal is sensitive to CaMKII modulation, our signal to noise is well above 
background uptake levels. In addition, the linearity of the uptake signal is well within our 
measurement range and we can theoretically detect either inhibition or upregulation of 
transfected transporter activity. We thus asked the question: Does the phenotypic 
regulation of astrocytic transporters by CaMKII result from regulation of EAAT1, 
EAAT2, or both transporters?  
 In order to answer this question, we applied CaMKII inhibitors (KN-93 and 
tat-CN21) and inhibitor controls (KN-92 and tat-CN21Ala) to EAAT1 and EAAT2 
transfected HEK293Ts and measured [3H]-glutamate uptake as described previously from 
our work in astrocytes (Ashpole, Chawla et al. 2013). We observed a significant 
reduction of 34% in [3H]-glutamate uptake associated with KN-93 and tat-CN21 in 
EAAT1 transfected HEK293T cells compared to inactive controls KN-92 and tat-
CN21Ala (Figure 8A). Interestingly, EAAT2 mediated glutamate uptake was not altered 
by CaMKII inhibition or the inhibitor controls (Figure 8B). These data suggest that 
CaMKII inhibition using pharmacological agents diminishes EAAT1 but not EAAT2 
mediated glutamate uptake, appearing to have divergent effect on the two predominant 
astrocytic transporters for glutamate. This phenotype was further substantiated in a model 
	 86 
of transfected A172s (a glioblastoma cell line), wherein CaMKII inhibition reduced [3H]-
glutamate uptake by 34% in EAAT1 but not EAAT2 transfected A172s, substantiating 
our findings in HEK293Ts (Figures 9A and 9B). Thus, in two very different 
backgrounds, we observed that pharmacological CaMKII inhibition consistently targets 
glutamate uptake occurring via EAAT1, while leaving EAAT2-mediated glutamate 
unaffected. While this observation is suggestive of minimal off-target activities of our 
CaMKII inhibitors, our confidence in these findings is further supported by the inactive 
controls for our pharmacological agents not producing alterations in glutamate uptake for 
both EAAT1 and EAAT2. However, we wanted to use an alternative approach to 
corroborate our pharmacological findings in order to strengthen our conclusion.  
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Figure 8: Pharmacological CaMKII inhibition reduces EAAT1 but not EAAT2 mediated 
[3H]-glutamate uptake in HEK293T cells. Average [3H]-glutamate uptake in A, EAAT1 
(n=6-9, ± S.E.M) and B, EAAT2 transfected cells (n=6, ± S.D.) normalized to transfected 
untreated HEK293T cells. Inhibitor controls KN-92 and tat-CN21 Ala and inhibitors KN-
93 and tat-CN21 were used at a concentration of 5 µM, and applied to cells for 20 minutes 
prior to a 20 minute [3H]glutamate uptake measurement protocol. 10 µM UCPH-101 and 
10 µM TBOA were added to EAAT1 and EAAT2 transfected cells respectively as 
controls. The asterisk indicates a significant difference compared to transfected untreated 
control (*, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test). 
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Figure 9: Pharmacological CaMKII inhibition reduces EAAT1 but not EAAT2 
mediated [3H]-glutamate uptake in A172 glioma cells. Average [3H]-glutamate uptake 
in A, EAAT1 (n=9, ± S.E.M) and B, EAAT2 transfected cells (n=6, ± S.D.) normalized to 
transfected untreated A172 glioma cells. Inhibitors 5µM KN-92 and 5µM KN-93 were 
applied to cells for 20 minutes prior to a 20 minute [3H]-glutamate measurement protocol. 
The asterisk indicates significant difference compared with transfected untreated control 
(*, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test). 
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A dominant-negative version of CaMKII (Asp136Asn) produces a reduction in 
EAAT1 but not EAAT2-mediated [3H]-glutamate uptake 
 As an orthogonal approach to our pharmacological data that implicate CaMKII 
regulation of EAAT1 but not EAAT2, we wanted to genetically inhibit CaMKII. In 
rodent cultured cortical astrocytes, γ and δ CaMKII have been reported to be the 
predominant isoforms (Takeuchi, Yamamoto et al. 2000, Vallano, Beaman-Hall et al. 
2000). This is in contrast with neuronal cells, where α and β CaMKII are expressed in 
much higher levels. Using pharmacology, we presumably targeted the action of both γ 
and δ CaMKII in astrocytes, as the inhibitors do not possess isoform specificity. Because 
δ CaMKII is believed to be the predominant CaMKII isoform in astrocytes (Takeuchi, 
Yamamoto et al. 2000), we generated a dead mutant (Asp136Asn) in δCaMKII by 
replacing a critical aspartate residue in the substrate binding site with an asparagine 
(Chao, Stratton et al. 2011). Both Asp136Asn and wild-type δCaMKII were sub-cloned 
into vectors expressing an N-terminal YFP tag and co-transfected into HEK293T cells 
with EAAT1 or EAAT2. We first characterized the autonomous activity of this mutant 
using [γ-32P] incorporation assays into the CaMKII substrate, AC-2. Surprisingly, we did 
not detect a reduction in [γ-32P] incorporation in cells transfected with Asp136Asn 
δCaMKII compared to untransfected and vector control (YFP-tagged vector); in fact we 
observed a slight increase in [γ-32P] incorporation compared to wild-type δCaMKII 
(Figure 10A). It is possible that endogenous kinase may be overriding the inhibitory 
effects of Asp136Asn δCaMKII in our [γ-32P] assays; however, our [3H]-glutamate 
uptake data in Figure 10D and Figure 10E suggest that we may be failing to detect an 
alteration in CaMKII activity. Furthermore, in our experiments, % autonomy upon 
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transfection of δCaMKII wild-type consistently decreases (12±2%) compared to 
untransfected (20±2%) and vector control conditions (19±4%); a similar trend is 
observed in Figure 11. This may be accounted for by a 3-4 fold increase in dependent 
CaMKII activity.  
 We co-transfected YFP Asp136Asn δCaMKII into HEK293T cells with either 
mCherry EAAT1 or mCherry EAAT2. We find that transfection efficiencies in all 
conditions studied are not significantly different (Figures 10B and C). YFP Asp136Asn 
δCaMKII/ mCherry EAAT1 and YFP Asp136Asn δCaMKII/ mCherry EAAT2 appear to 
be expressed in a similar manner intracellularly, based on a fluorometric readout. 
Although our [γ-32P] incorporation data were puzzling, as the cellular distribution of YFP 
Asp136Asn δCaMKII did not appear to be different from wild-type δCaMKII and thus 
we decided to perform glutamate uptake assays.  
 Surprisingly, overexpression of Asp136Asn δCaMKII produced a 50% ± 2.9 
reduction in EAAT1, but not EAAT2, mediated [3H]-glutamate uptake in HEK293T cells 
(Figures 10D and E) compared to EAAT1/2 only transfected cells. We independently 
tested the effect of wild-type δCaMKII on [3H]-glutamate uptake and did not find a 
significant difference compared to untreated transfected cells (depicted in Figure 11F), 
so chose not to include this control in this particular experiment. The most likely 
explanation for this result is that the dead CaMKII mutant protein produces a dominant 
negative phenotype as described previously for another kinase dead variant of CaMKII 
(Kabakov and Lisman 2015).Given that we observe an alteration in EAAT1- but not 
EAAT2-mediated glutamate uptake suggests the effect associated with Asp136Asn 
δCaMKII transfection is isoform specific to EAAT1. Although our [γ-32P] assays (Figure 
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10A) do not support this idea, our functional glutamate uptake measurements suggest 
subunits of Asp136Asn δCaMKII combine with δCaMKII wild-type and potentially 
override basal signaling associated with wild-type CaMKII. In sum, this genetic approach 
is revealing in both being consistent with pharmacological inhibition of CaMKII 
regulating EAAT1, but also in the fact that along with pharmacological inhibitors, 
expression of the dominant negative CaMKII did not appear to alter glutamate uptake 
mediated by EAAT2.   
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Figure 10: Asp136Asn δCaMKII overexpression reduces EAAT1 but not EAAT2 
mediated [3H]-glutamate uptake in HEK293T cells. A: Ca2+/CaM-dependent and -
independent [32P] incorporation into the CaMKII substrate AC-2 using a mCherry vector 
control, wild-type δCaMKII and Asp136Asn δCaMKII. % autonomy represents 
autonomous/total CaMKII activity. Shown are representative images of Asp136Asn 
δCaMKII in B: EAAT1 transfected and C: EAAT2 transfected HEK293T cells. Images are 
viewed under red fluorescent light (left), green fluorescent light (center) and merged (right). 
Average [3H]-glutamate uptake in D: EAAT1 (n=6, ± S.D.) and E: EAAT2 transfected cells 
(n=6, ± S.D.) normalized to transfected untreated HEK293T cells. 2.5µg cDNA for 
Asp136Asn δCaMKII was transfected into HEK293T cells, and [3H]-glutamate uptake was 
measured 16-22 hours later. 10µM UCPH-101 and 10µM TBOA were added to EAAT1 and 
EAAT2 transfected cells respectively as controls. The asterisk indicates a significant 
difference compared to transfected untreated control vector (*, p≤0.05, one-way ANOVA, 
post-hoc Dunnett’s test). 
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CaMKII autophosphorylation mutants at Thr287 do not alter glutamate uptake via 
either EAAT1 or EAAT2 
 Autophosphorylation of δCaMKII at Thr287 renders the kinase autonomously 
active, enhancing its ability to impact downstream cellular functions (Lai, Nairn et al. 
1987, Miller, Patton et al. 1988, Hudmon and Schulman 2002). While there is 
autonomously active CaMKII in our naïve cultured HEK293T cells (21.64% ± 2.3, 
Figure 11A), we generated phosphorylation-site Thr287 mutants to examine whether the 
level of autonomous kinase activity alters EAAT1 or EAAT2 transporter function. First, 
we generated a Thr287Asp mutant that replaces threonine with a negatively charged 
aspartate residue to mimic phosphorylation, theoretically augmenting the level of 
autonomous activity. Second, we generated a Thr287Val mutant that replaces the 
threonine residue with a valine, a non-phosphorylatable amino acid that hypothetically 
reduces the level of autonomous activity. We ran [γ-32P] incorporation assays to test 
whether our mutants did, in fact, produce the alterations we hypothesized in autonomous 
CaMKII activity. As described previously, we observe that transfection of wild-type 
δCaMKII marginally decreases % autonomous kinase activity from 21±2% to 11±2% 
(Figure 11A). Thr287Asp, a phospho-mimetic, has 74±6% autonomous activity whereas 
Thr287Val, the non-phosphorylatable mutant, is 4±1% autonomous as a function of AC-2 
phosphorylation, as compared to untransfected HEK293T cells that exhibit 21±2% 
autonomous activity.   
 We transfected YFP-tagged versions of δCaMKII wild-type, Thr287Asp and 
Thr287Val into HEK293T cells. We additionally co-transfected mCherry-tagged EAAT1 
into HE293Ts to observe cellular localization and distribution. δCaMKII wild-type, 
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Thr287Asp and Thr287Val all localized in a uniform cellular distribution in EAAT1 
transfected HEK293Ts (Figures 11 B-D). Next, we measured the consequence of 
δCaMKII Thr287 autophosphorylation mutants on [3H]-glutamate uptake by EAAT1 or 
EAAT2. Surprisingly, we find that neither the Thr287Asp nor the Thr287Val mutant 
alters either EAAT1 mediated (Figure 11E) or EAAT2 mediated glutamate uptake 
(Figure 11F). UCPH-101, an EAAT1 inhibitor, and TBOA, an EAAT2 inhibitor, 
produced reductions in glutamate uptake as previously shown, suggesting that our 
experimental paradigm is sound. Overall, these data suggest that reducing or enhancing 
CaMKII activity below or above basal cellular levels respectively in HEK293T cells does 
not further enhance glutamate transporter-mediated glutamate uptake.  
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Figure 11: Multiple δCaMKII Thr287 autophosphorylation states do not alter 
EAAT1 and EAAT2 mediated [3H]-glutamate uptake in HEK293T cells. A: 
Ca2+/CaM-dependent and -independent [32P] incorporation into the CaMKII substrate AC-
2 using a mCherry vector control, wild-type, Thr287Asp, and Thr287VAl δCaMKII. % 
autonomy represents autonomous/total CaMKII activity. Shown are representative images 
of wild-type, Thr287Asp, Thr287Val δCaMKII in B: wild-type δCaMKII C: T287D 
δCaMKII and D: T287V δCaMKII in EAAT1 transfected HEK293T cells. Images are 
viewed under red fluorescent light (left), green fluorescent light (center) and merged/white 
light (right). Average [3H]-glutamate uptake in E: EAAT1 (n=6, ± S.D.) and F: EAAT2 
transfected cells (n=6, ± S.D.) normalized to transfected untreated HEK293T cells. 2.5µg 
cDNA for wild-type δCaMKII, Thr287Asp δCaMKII and Thr287Val δCaMKII were 
transfected into HEK293T cells co-transfected with EAAT1 or EAAT2, and [3H]-
glutamate uptake was measured 16-22 hours later. 10µM UCPH-101 and 10µM TBOA 
were added to EAAT1 and EAAT2 transfected cells respectively as controls. 
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CaMKII activation by ionomycin does not alter glutamate uptake via EAAT1  
 We were surprised that neither Thr287Asp nor Thr287Val produced 
alterations in [3H]-glutamate uptake. Thus, we decided to utilize a different methodology 
to enhance CaMKII signaling by using ionomycin, a known calcium ionophore. Although 
ionomycin has been reported to increase CaMKII activity, we wanted to test it in our 
system. In order to maximize the possible effect we would see, we overexpressed 
δCaMKII in HEK293T cells increasing Ca2+/CaM-dependent activity by ~3-3.5 fold 
compared to untransfected cells (Figure 12A). We tested an acute (1 minute) and a 
chronic (20 minutes) time point for ionomycin treatment, using ionomycin at 10µM, 
previously described to be effective in transfected HEK cells (Hudmon, Lebel et al. 
2005). We find that ionomycin increases [γ-32P] incorporation into AC-2 at both the 1 
and 20 minute time points, suggesting that CaMKII activation is both rapid and sustained 
following ionomycin treatment (Figures 11 A and B). Compared to % autonomy 
observed in δCaMKII-transfected cells, ionomycin treatment increases % autonomy 
significantly whereas vehicle (MeOH) treatment has no effect (Figure 11B). Given these 
findings, we decided to test the effect of ionomycin on [3H]-glutamate uptake. As we did 
not previously observe any alterations in EAAT2 mediated glutamate uptake, we decided 
to focus on EAAT1 mediated glutamate uptake. We transfected HEK293T cells with 
vector control (YFP-tagged vector) or YFP δCaMKII, subsequently treating cells with 
either MeOH or ionomycin for 20 minutes. We found that ionomycin does not alter 
glutamate uptake in δCaMKII-transfected HEK293T cells (Figure 12C), corroborating 
our data in Figure 11E depicting no change in glutamate uptake when a δCaMKII 
Thr287Asp mutation is introduced. In total, neither site-directed mutagenesis 
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(phosphorylation-site mutants of the autophosphorylatable residue Thr287 in δCaMKII) 
nor enhancing intracellular calcium signaling (application of ionomycin) alter glutamate 
uptake in HEK293T cells expressing EAAT1 and EAAT2.  
 Data thus far suggest EAAT1 regulation by CaMKII. To date, none of the 
glutamate transporters have been described as CaMKII substrates, however one of the 
questions that arises from our experiments thus far is whether EAAT1 does, in fact, 
interact with CAMKII and serve as a CaMKII substrate? The next part of my dissertation 
addresses this question.  
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Figure 12: Ionomycin does not alter glutamate uptake in transfected HEK cells. A: 
Ca2+/CaM-dependent and -independent [32P] incorporation into the CaMKII substrate 
AC-2 in untransfected and δCaMKII wild-type HEK293T cells (n=3, ± S.D) treated with 
vehicle (MeOH), and ionomycin (10 µM for 1 and 20 mins). B: % autonomy represented 
as autonomous/total CaMKII activity from Panel A. C: Average [3H]-glutamate uptake in 
EAAT1 and YFP vector control/ δCaMKII wild-type transfected cells (n=3, ± S.D) 
normalized to vehicle-treated (MeOH) vector control HEK293Ts. 10 µM Ionomycin was 
added to the cells for 20 mins during [3H]-glutamate addition and [3H]-glutamate uptake 
was measured following this incubation.   
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Activated δCaMKII does not appear to bind either EAAT1 or EAAT2 
 In order to test whether CaMKII interacts with glutamate transporters, we co-
transfected δCaMKII and 3x FLAG-tagged EAAT1 and EAAT2 in HEK293T cells. We 
subsequently activated δCaMKII with 20 mins of ionomycin treatment (increase in % 
autonomy depicted in Figures 12 A and B), and tested for interaction between CaMKII 
and the glutamate transporters. We pulled down the transporters using a FLAG-antibody, 
and ran a Western blot testing our pull-down and δCaMKII interaction using a pan-
CAMKII antibody. For controls, we ran lysates from our experimental transfection 
conditions:  δCaMKII only, δCaMKII/3x FLAG EAAT1, and δCaMKII/3x FLAG 2. 
First, we find that we can detect substantial pull-down for both 3x FLAG-tagged EAAT1 
and EAAT2 (in both the pulldown represented on the left side of the blot and lysate 
represented on the right side of the blot, Figure 13). The bottom bond observed at 
~55kDa appears to be an artifact generated when the FLAG antibody is used (as it is 
observed when only δCaMKII is transfected and the FLAG antibody is used to pulldown 
protein). δCaMKII does not appear to interact with either EAAT1 or EAAT2, as 
evidenced by lack of detection on the left side of the blot when the pan CaMKII antibody 
is used for Western blot detection. However, it is clear that our pan CaMKII antibody 
does detect δCaMKII as it is observed in all three of our experimental conditions on the 
right side of the blot. In conclusion, ionomycin-activated δCaMKII does not appear to 
bind either glutamate transporter, EAAT1 or EAAT2.  
  
	 100 
 
  
Figure 13: Autophosphorylated δCaMKII does not interact with either EAAT1 or 
EAAT2. Transfected δCaMKII was activated for 20 mins using ionomycin (10µM), and co-
immunoprecipitated with no additional cDNA (lanes 1 and 2), 3x FLAG EAAT1 (lanes 3 and 
4), or 3x FLAG EAAT2 (lanes 5 and 6) in HEK293T cells. Lysate (lanes 8,-10) represented 
total transfected cDNA. Antibodies used for Westerns were mouse anti-FLAG and rabbit anti-
pan CaMKII. 
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CaMKII phosphorylates a GST-fusion protein expressing the N terminus of EAAT1  
 Although CaMKII does not appear to bind either glutamate transporter, we 
wanted to test whether either transporter is a CaMKII substrate, as our data thus far our 
data suggests CaMKII regulates EAAT1 function. To address this, we generated GST-
fusion proteins of the intracellular N- and C-termini of both EAAT1 and EAAT2. GST 
EAAT1 and -2 N- and C- termini were captured by glutathione resin, and then 
phosphorylated by purified human activated δCaMKII. Phosphorylation was measured by 
incorporation of radiolabeled phosphate [γ-32P] into the substrates (upper image, Figure 
14), and exposed onto an imaging screen for visualization. Measurements were 
normalized to Coomassie staining (lower image, Figure 14), a stain that binds to protein, 
to control for variance in total protein used in each treatment. A GST only lane served as 
a negative control (lane 1) while GluR1, a subunit of the AMPA receptor, served as a 
positive control (lanes 6 and 7, Figure 14). We observed comparable loading (lower 
image) among the four experimental GST fusion proteins as well as the GST control. 
GluR1 is a known substrate of CaMKII; we loaded variable concentrations as we 
expected the phosphorylation signal to be high. Qualitatively, we observe the strongest 
phosphorylation signal at the N terminus of EAAT1 that corresponds with the largest 
band of GST EAAT1 that likely represents unproteolysed fusion protein. We also 
observed a weak phosphorylation signal for the N terminus of EAAT2, however since the 
signal was barely detectable and we loaded a greater amount for the GST EAAT2 N 
terminus compared to the other fusion proteins we did not think this phosphorylation was 
of a significant amount (Figure 14).  
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Figure 14: CaMKII phosphorylates a GST-fusion protein expressing the N-
terminus of EAAT1. Representative image of [γ-32] incorporation (top) and Coomassie 
gel (lower) of phosphorylated GST-fusion proteins phosphorylated by δCaMKII. Lanes 
contain 1: GST only, 2: GST EAAT1 N-terminus, 3: GST EAAT1 C-terminus, 4: GST 
EAAT2 N-terminus, 5: GST EAAT2 C-terminus, 6 and 7: GST GluR1 
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Utilization of the SPOTS blot strategy to identify potentially phosphorylatable 
residues in EAAT1 and EAAT2 by CaMKII 
 To identify specific residues phosphorylated by δCaMKII, intracellular regions 
of both EAAT1 and EAAT2 were tiled using immobilized peptide synthesis using the 
SPOTS approach as recently described (Ashpole, Herren et al. 2012). As a frame of 
reference, the predicted structure of EAAT1 is represented in Figure 15A, with 8 trans-
membrane domains, intracellular N- and C- termini and 3 short intracellular loops (L1-
L3). The predicted structure for EAAT2 is represented in Figure 15B. Similar to the 
predicted structure for EAAT1, EAAT2 has intracellular N- and C-termini. Furthermore, 
EAAT2 has 4 intracellular loops.  Each 15-amino acid long peptide generated by the 
SPOTS approach differs by 1 amino acid, so for example as depicted in Figure 15C 
peptide 1 would span residues 1-15 of a given protein, peptide 2 would span residues 2-
16, and so on. A blot was generated with the entirety of the predicted intracellular protein 
sequences of EAAT1 and EAAT2, as represented in Figure 15C. A blot containing all 
the testable peptides is thus treated at the same time, minimizing variability that may 
occur owing to differences during kinase activation and application onto membrane. 
Known CaMKII substrates GluR1 (described previously) and vimentin, an intermediate 
filament protein, were included on the tiled array as positive controls (two bars to the far 
right, Figures 15D and 15E). In vitro phosphorylation of EAAT1 by CaMKII generated 
a number of potentially phosphorylated peptides (~peptides 18-23) in the middle of the N 
terminus of EAAT1, with a small spike observed at the very end of the N terminus 
(~peptides 32-33). Two potential residues identified from this peptide tiling analysis in 
Figure 15D were Thr26 and Thr37. Lack of [γ-32P] incorporation in the predicted 
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intracellular loops (L, L2, and L3) and the C terminus suggest that these regions do not 
contain CaMKII phosphorylation sites. In vitro phosphorylation of EAAT2 peptides by 
CaMKII generated a number of potentially phosphorylated peptides at the end of the C 
terminus (~peptides 137-157) as well as one peptide in intracellular loop 3  (Figure 15E). 
However, as we did not observe functional changes in glutamate uptake in EAAT2 upon 
altering CaMKII activity, we focused on EAAT1. 
 We decided to continue using the SPOTS blot strategy to replace potentially 
phosphorylated residues with an alanine, a non-phosphorylatable residue. First, we 
examined the two EAAT1 residues- Thr26 and Thr37. We synthesized the best peptides 
containing these residues as both wild-type and alanine mutations (as well as a double 
mutant) to test if specific threonine residues were phosphor-acceptors for CaMKII. Wild-
type EAAT1 comprised of residues Arg23-Thr37, to be consistent with the 15mers used 
in Figure 15D. Ala mutants of both Thr26 and Thr37 as well as the double Ala mutant 
produced a significant reduction in CaMKII phosphorylation compared to wild-type 
(Figure 16). Specifically, Thr26Ala produced a reduction of 23±3%, while Thr37Ala and 
Thr26AlaThr37Ala produced a reduction of 62±1% and 63±3% respectively compared to 
wild-type.  
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Figure 15: δCaMKII phosphorylation of EAAT1 using SPOTS blot analysis identified 
two residues in the N terminus, Thr26 and Thr37, that are important for 
phosphorylation. A, Schematic of EAAT1 protein. B, Schematic of EAAT2 protein. C, 
Schematic of generation of 15 amino acid long peptides using the SPOTS blot strategy on a 
derivatized cellulose membrane. D, Average [γ-32] phosphorylation per area (PSL/mm2) for 15 
amino acid long peptides of the intracellular portion of EAAT1. E, Average [γ-32] 
phosphorylation per area (PSL/mm2) for 15 amino acid long peptides of the intracellular 
portion of EAAT2. 
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Figure 16: δCaMKII phosphorylation of EAAT1 mutants using SPOTS blot analysis 
identified two residues in the N terminus, Thr26 and Thr37, that are important for 
phosphorylation. Average [γ-32] phosphorylation per area (PSL/mm2) for an n=3± S.D of 15 
amino acid long peptides representing EAAT1 23-37 wild-type, EAAT1 23-37 Thr26Ala, 
EAAT1 23-37 Thr37Ala and EAAT1 23-37 Thr26Ala/Thr37Ala. Representative images for 
each condition are shown to the right of the bar, with an n=3± S.D performed for each 
condition. The asterisk indicates significant difference compared with wild-type control (*, 
p≤0.05, one-way ANOVA, post-hoc Dunnett’s test). 
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GST fusion proteins suggest Thr37 in EAAT1 is phosphorylated by CaMKII  
 Although potentially phosphorylated residues were identified in both EAAT1 
and EAAT2, we decided to pursue only EAAT1 from hereon due to two reasons. One, we 
did not identify any functional contribution related to CaMKII signaling as a regulator of 
EAAT2 function (glutamate uptake, Figures 8 and 9). Second, although SPOTS blot 
analysis of the intracellular portions of EAAT2 suggested residues phosphorylated by 
CaMKII, alanine mutagenesis using the same methodology did not further suggest this is 
the case (data not shown). Thus, we focused our work on EAAT1 from hereon.  We used 
GST-fusion proteins as previously described (Figure 14), of the EAAT1 N-terminus to 
parse out phosphorylation of residues Thr26 and Thr37 by CaMKII. Again, Ala 
substitutions were generated for Thr26 and Thr37, as well as a double Ala mutant, and 
we performed an in vitro phosphorylation reaction by δCaMKII. Thr37Ala produced a 
significant reduction in [γ-32P] signal compared to wild-type (53±1%), while the double 
mutant produced a reduction that was not significant (Figure 17B, representative image 
in Figure 17A). These data confirmed our findings from Figure 16. However, Thr26Ala 
produced an increase in phosphorylation which was inconsistent with the SPOTS blot 
data generated in Figure 16. It is possible that the Thr26Ala mutation results in a mis-
folded GST fusion protein that may cause [γ-32P] to bind more strongly to the protein. 
Furthermore, this protein mis-folding may make another serine or threonine residue 
increasingly accessible to [γ-32P], causing an increase in radioactive signal detected. Even 
with proper folding, the possibility of increased phosphorylation of another residue is 
likely. The non-significant reduction in [γ-32P] incorporation observed in the 
Thr26Ala/Thr37Ala mutant (compared to wild-type) is in agreement with this data- if one 
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Ala mutation increases [γ-32P] incorporation whereas the other one decreases it, the 
double mutant will not provide a significant alteration in phosphorylation, which appears 
to be the case. Although we are unsure of the exact reason underlying this discrepancy, 
we next decided to measure the effect of mutations at both these residues on [3H]-
glutamate uptake. 
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Figure 17: GST-fusion proteins suggest Thr37 is a potential phospho-site for 
δCaMKII. A, Representative image of [γ-32] incorporation (top) and Coomassie gel 
(below) of GST-fusion proteins (wild-type and mutant EAAT1) phosphorylated by 
δCaMKII. Lanes contain 1: GST only, 2: GST EAAT1 N terminus wild-type, 3: GST 
EAAT1 N terminus Thr26Ala, 4: GST EAAT1 N terminus Thr37Ala, 5: GST EAAT1 N 
terminus Thr26Ala Thr37Ala, and 6: GST GluR1. B, Average densitometry for [γ-
32]/Coomassie for an n=4± S.D for GST-EAAT1 N terminus mutant phosphorylation. The 
asterisk indicates significant difference compared with wild-type control (*, p≤0.05, one-
way ANOVA, post-hoc Dunnett’s test). 
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A phosphorylation event at EAAT1 Thr37 by CaMKII mediates alterations in 
glutamate uptake 
 To identify the functional significance of the Thr26 and Thr37 
phosphorylation sites on EAAT1 mediated glutamate uptake, we mutated Thr26 and 
Thr37 into Ala residues in order to block phosphorylation. Furthermore, we generated 
double Ala mutants to determine the contribution of both sites. Only the Thr37Ala and 
Thr26Ala/Thr37Ala produced a significant reduction in [3H]-glutamate uptake (Figure 
18A). Thr26 does not appear to regulate alterations in [3H]-glutamate uptake mediated by 
EAAT1 as the Thr26Ala mutant does not produce any change in glutamate uptake. We 
next mutated Thr26 and Thr37 into Asp residues, to mimic the negative charge as a 
consequence of phosphorylation (thereby generating phosphomimetics). Additionally, we 
generated a double Asp mutant (Thr26Asp/Thr37Asp) to determine whether there was an 
additive contribution by both sites. Surprisingly, neither Thr37Asp nor 
Thr26AspThr37Asp mutants increased EAAT1 mediated glutamate uptake, suggesting 
that CaMKII regulation of this process may occur to maintain homeostatic function.  
 Next, to test the specificity of Thr37 and the KN93 drug in regulating EAAT1, 
we performed an occlusion experiment to determine if the presence of both the CaMKII 
inhibitor and the Ala substitution were synergistic or additive. Corroborating our 
observation in Figure 18A, EAAT1 in the Thr37Ala background produced a significant 
reduction in [3H]-glutamate uptake compared to EAAT1 wild-type (Figure 18B). When 
we applied CaMKII inhibitor, KN-93, onto EAAT1 Thr37Ala, we observed that the 
Thr37 mutation partially occluded the KN-93 effect. [3H]-glutamate uptake was 
significantly further reduced compared to KN-92 and control conditions (Figure 18B), 
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suggesting CaMKII may have direct (phosphorylation) effects on a previously 
unidentified site or possibly indirect effects on EAAT1 mediated glutamate uptake via 
regulating EAAT1’s function via its interaction with another factor/protein.  
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Figure 18: CaMKII phosphorylation of EAAT1 Thr37 regulates [3H]-glutamate uptake 
in transfected HEK293Ts. A, Average [3H]-glutamate uptake in EAAT1 wild-type, and 
EAAT1 mutants: Thr26Ala, Thr26Asp, Thr37Ala, Thr37Asp, Thr26AlaThr37Ala, 
Thr26AspThr37Asp (n=6, ± S.D.) normalized to transfected untreated HEK293T cells. B, 
Average [3H]-glutamate uptake in EAAT1 wild-type and EAAT1 Thr37Ala mutant, with 
application of inhibitors 5µM KN-92 and 5µM KN-93 for 20 minutes prior to a 20 minute 
[3H] uptake measurement protocol. The asterisk indicates significant difference compared 
with transfected untreated control (*, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test) and 
the hatched bar indicates a significant difference compared with transfected untreated control 
(#, p≤0.05, one-way ANOVA, post-hoc Dunnett’s test). 
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DISCUSSION 
General Conclusions 
 The differential ability of cellular glutamate uptake to diminish extracellular 
glutamate concentrations in order to prevent glutamate-induced excitotoxicity was 
discovered almost four decades ago (Hertz, Schousboe et al. 1978, Drejer, Larsson et al. 
1982, Choi 1992). However, parsing out underlying mechanisms for a complex process 
such as glutamate uptake was complicated owing to the contribution by numerous cell 
types and multiple proteins. The molecular identity of the five known glutamate 
transporter subtypes was discovered through the 1990s (Kanai and Hediger 1992, Pines, 
Danbolt et al. 1992, Storck, Schulte et al. 1992, Fairman, Vandenberg et al. 1995, Arriza, 
Eliasof et al. 1997). These findings were pivotal as they allowed researchers to examine 
the contribution and regulation of each glutamate transporter subtype individually, 
particularly in heterologous expression systems. It is now known that the physiological 
pathways involving different cellular signaling proteins can result in differential 
alterations in surface expression, total expression, and activity of the glutamate 
transporters. Furthermore, subsequent pathological changes can alter glutamate 
transporter regulation. The findings in this dissertation uncover a novel regulation of the 
astrocytic glutamate transporter subtype EAAT1 by the ubiquitously expressed 
serine/threonine protein kinase CaMKII. Interestingly, our data suggests that it is the 
autonomously active form of CaMKII that is necessary for the homeostatic regulation 
astrocytic glutamate uptake. Since intracellular Ca2+ levels can change rapidly, it is 
thought that CaMKII autonomy serves as a key form of molecular memory for cellular 
Ca2+ signals even when the Ca2+ transient subsides. These findings support the idea that 
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CaMKII previously activated in the cell by Ca2+/CaM does, in fact, serve as an important 
form of a molecular memory device and regulates EAAT1 via phosphorylation.  
 The majority of our understanding of CaMKII function comes from studies 
performed in neurons. CaMKII has been implicated in a number of cellular processes 
such as calcium homeostasis, excitability, neurotransmitter synthesis/release and neuronal 
plasticity (reviewed in (Hudmon and Schulman 2002, Robison 2014)). Numerous reports 
suggest that a loss of both neuronal and astrocytic CaMKII signaling may be an important 
driver of excitotoxicity (Hajimohammadreza, Probert et al. 1995, Laabich and Cooper 
2000, Goebel 2009, Vest, O'Leary et al. 2010, Ashpole, Song et al. 2012, Ashpole, 
Chawla et al. 2013). Especially pertinent to our studies, pharmacological inhibition of 
astrocytic CaMKII resulted in dysregulated calcium homeostasis, altered mitochondrial 
membrane potential, excessive release of the gliotransmitter ATP and decreased 
glutamate uptake; functional changes that are associated with compromised neuronal 
survival (Ashpole, Chawla et al. 2013).  
 In this dissertation, data are presented that provide evidence suggesting 
CaMKII regulates astrocytic glutamate uptake via the novel substrate and glutamate 
transporter EAAT1, but not EAAT2.  This regulation appears to be two-pronged: it is 
partly dependent on CaMKII phosphorylation of the Thr37 residue on EAAT1, and partly 
appears to occur via an unidentified mechanism that is independent of phosphorylation at 
this particular site. The remainder of the regulatory effect could be accounted for by 
phosphorylation at another site on EAAT1 that our studies may have failed to identify, or 
by the action of CaMKII on another protein. Although there had been no studies 
describing glutamate uptake regulation by CaMKII when I had undertaken my 
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dissertation work, a recent study by Underhill et al describes the latter form of regulation 
(Underhill, Wheeler et al. 2015). This study reported CaMKII phosphorylation of DLG1, 
a scaffolding protein, which in turn regulated surface expression of a splice variant of 
EAAT2 termed EAAT2b that differs at the C-terminus (Underhill, Wheeler et al. 2015). 
Utilizing MDCK epithelial cells and astrocyte cultures as model systems, this report also 
found that CaMKII did not alter surface expression of the splice variant EAAT2a (the 
splice variant I studied), a finding that is consistent with our observation that alterations 
in CaMKII activity do not affect glutamate activity through EAAT2a. In sum, CaMKII 
appears to differentially regulate glutamate uptake via the astrocytic glutamate 
transporters and their splice variants.  
 
Cultured cortical astrocytes as a model system 
 Astrocytes are involved in a wide array of functions in the brain. These include 
but aren’t restricted to buffering potassium ions, controlling extracellular pH, controlling 
cerebral blood flow, and taking up glutamate and GABA (Tschirgi and Taylor 1958, 
Orkand, Nicholls et al. 1966, Martinez-Hernandez, Bell et al. 1977, Kimelberg 1987). In 
order to examine astrocytic function outside of the intact brain, astrocytes were cultured 
to study specific cellular functions. In particular, cultured astrocytes were first utilized to 
study glutamate uptake almost four decades ago (Hertz, Schousboe et al. 1978, Drejer, 
Larsson et al. 1982). Since then, they have been extensively utilized as a model system 
for a number of reasons. First, dissociated postnatal astrocyte cultures represent a mature 
and differentiated cell line that can be used for several weeks in culture once harvested. 
Additionally, it is known that numerous cell types and brain tissue express a variety of 
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glutamate transporter isoforms (discussed in Background). Pure cortical astrocytes 
cultures thus provide a system that has minimal other confounding factors from other 
cells or transporter subtypes. Specifically, astrocytes primarily express the EAAT1 and 
EAAT2 (Rothstein, Dykes-Hoberg et al. 1996, Tanaka, Watase et al. 1997, Watase, 
Hashimoto et al. 1998) while EAAT3 has been observed to express in a neuronal 
background (Kanai and Hediger 1992). However, both glial and neuronal cells can 
express glutamate transporters in addition to EAAT1, EAAT2 and EAAT3 as a function 
of tissue localization (refer to Table 1). For example, EAAT4 is exclusively expressed in 
the cerebellum (Fairman, Vandenberg et al. 1995), while EAAT5 is solely expressed in 
retinal glial cells (Arriza, Eliasof et al. 1997). Thus, careful consideration needed to be 
put into generating and maintaining our dissociated astrocyte cultures. During our 
astrocyte culture generation protocol, we carefully excised the cortex away from the 
intact brain tissue, and ensured we did not support either the growth of neurons or 
oligodendrocytes by mechanical elimination (look at Materials and Methods). Upon 
characterization of our cultures using immunocytochemical analyses, we found that our 
cultures were primarily astrocytic (Figure 4), with minimal contamination by microglia 
and neurons. Thus, cortical astrocyte cultures represent a strong model system to study 
the regulation of astrocytic glutamate transporters by CaMKII.  
 Astrocytes are non-excitable cells that are found in close proximity to and 
interact with various other cells types, such as neurons, microglia, oligodendrocytes, and 
vascular cells, in the intact brain. While having an isolated culture enables us to study 
glutamate uptake occurring only via astrocytes, it is important to recognize that various 
other cells may provide supporting functions for those performed by astrocytes, much 
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like an astrocyte provides for a neuron. It is clear that astrocytes function differently in 
culture versus brain slices versus in an intact brain. For example, the astrocytic protein 
GFAP which serves as a marker for reactive changes and astrogliosis (Eng and Ghirnikar 
1994) is not highly expressed in an intact brain or in brain slices, but is expressed at high 
levels in astrocyte cultures (Kimelberg, Cai et al. 2000). Furthermore, although GFAP is 
commonly used as a protein marker for astrocytes and all cells that express GFAP are 
considered to be astrocytes, all astrocytes do not express GFAP. Another example is that 
of the developmental protein and a marker of immature glial and neuronal cells, nestin. 
The nestin protein is expressed by most astrocytes in primary dissociated culture (Gallo 
and Armstrong 1995), a perplexing observation suggesting that the cells obtain a more 
primitive phenotype. Lastly, astrocyte cultures have also been described to express 
proteins typically associated with pathological states such as a proteoglycan form of the 
Alzheimer’s protein β-amyloid precursor protein (APP), which is expressed in injured 
brain but not detectable in normal brain tissue (Oohira, Kushima et al. 1995). It is clear 
that astrocytes are highly plastic cells that alter rapidly in response to their environment. 
Numerous reports thus suggest cultured astrocytes may exhibit a more primitive and 
reactive astrocytic morphology and protein expression compared to intact astrocytes, 
which is an important limitation to consider when using dissociated glial cells as a model 
system.  
 Early studies indicated low levels of glutamate uptake in the rodent brain at birth, 
which increased to adult levels within the first few weeks (Schousboe, Lisy et al. 1976, 
Schmidt and Wolf 1988, Cohen and Nadler 1997), although at this time the molecular 
determinants underlying this functional consequence were unknown. With the increased 
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utilization of antibodies, immunofluorescence and immunoblotting studies reported that 
GLAST and GLT proteins specifically were present at early stages of development, but at 
very low concentrations (Ullensvang, Lehre et al. 1997). In fact, GLT-1 was barely 
detectable in the newborn rat while GLAST levels were more easily detectable. The 
expression of both these proteins increased with age and reached maximal expression at 5 
weeks of age (Furuta, Rothstein et al. 1997, Ullensvang, Lehre et al. 1997). Interestingly, 
the expression pattern that occurs in embryonic rats is similar to the pattern observed in 
dissociated rodent cultures where GLAST is the primary astrocytic glutamate transporter 
with GLT-1 being expressed at much lower levels (Gegelashvili, Danbolt et al. 1997, 
Swanson, Liu et al. 1997). These findings suggest that removing astrocytes from their 
native environment causes the cells to revert to a more primitive phenotype. Low levels 
of GLT-1 expression could explain the lack of CaMKII regulation we observe, although 
we did supplement our astrocyte growth media with growth factors that may lead to 
increased GLT-1 expression. In order to substantiate these findings however, we use 
HEK293T cells as a heterologous expression system to study the regulation of the distinct 
astrocytic glutamate transporters in which we would have detected CaMKII regulation of 
EAAT2.  
 
HEK293T cells as a model system  
 The HEK293T cell line affords numerous benefits as a model system for 
heterologous expression: one can rapidly and inexpensively reproduce and maintain 
them, they are easily and efficiently transfected using a number of different transfection 
methodologies and they have a high efficiency of transfection and protein production 
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(Thomas and Smart 2005). In fact, HEK cells have been used and characterized 
previously to study glutamate uptake (Dunlop, Lou et al. 1999, Berry, Hayes et al. 2005, 
Peacey, Miller et al. 2009).  
 Glutamate transporters exist as homomeric trimers, with the exception of inter-
subunit interaction being described between only EAAT3 and EAAT4 thus far 
(Nothmann, Leinenweber et al. 2011). Our data suggests that we achieved a 46 ± 7% and 
43 ± 9% transfection efficiency for EAAT1 and EAAT2 cDNA in HEK293T cells 
respectively, which resulted in a subsequent 3.08 ± 0.14 fold and 3.31 ± 0.32 fold 
increase in glutamate uptake (Figure 7). The low levels of endogenous uptake in HEK 
cells have been attributed to the expression of the glutamate transporter EAAC1/EAAT3 
(Kanai and Hediger 1992, Shayakul, Kanai et al. 1997). Inter-subunit interaction has not 
been described between EAAT1, EAAT2, and EAAT3, and thus we can assume that the 
increase in glutamate uptake observed is mediated by homotrimers of EAAT1 and 
EAAT2.  
We are limited in using HEK cells as a model system in that if CaMKII regulated 
either glutamate transporter via an indirect phosphorylation event involving a protein that 
was not present in the native HEK cell environment, we would be unable to parse out this 
regulatory event. However, even though the HEK cell line does not provide the complex 
intercellular milieu associated with a differentiated native brain cell such as a neuron or 
an astrocyte, they are a powerful tool to study protein functions related to glutamate 
signaling, transporter and ion channel physiology. In order to address the limitations 
involving the complexity of HEK cells, we also used cultured cortical astrocytes and a 
glioma cell line to confirm our findings. Our heterologous system responds in a similar 
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manner as a primary astrocyte culture and a transformed astrocyte cell line to alterations 
in CaMKII signaling, strengthening the conclusions we arrived at in HEK293T cells.  
 
Isoform specificity of CaMKII regulation  
CaMKII is expressed in high levels in the brain; in some regions it accounts for 
up to 2% of total protein (Erondu and Kennedy 1985). Four distinct genes encode for 
CaMKII in eukaryotes: α, β, γ, and δ (for review see (Hudmon and Schulman 2002)). The 
α and β isoforms of CaMKII, which predominate in neurons (Erondu and Kennedy 1985), 
have been found to play important roles in synaptic plasticity, cell survival, and 
excitability in a neuronal context. Cultured cortical astrocytes express the γ and δ 
isoforms of CaMKII (Takeuchi, Yamamoto et al. 2000, Vallano, Beaman-Hall et al. 
2000), which are expressed in a number of other tissues such as skeletal muscle, pancreas 
and the heart (Ouimet, McGuinness et al. 1984, Tobimatsu and Fujisawa 1989).  
In our studies, we used a combination of pharmacological and genetic 
manipulations to address the regulatory role of CaMKII with respect to astrocytic 
glutamate uptake. To elicit pharmacological inhibition, we utilized the small molecule 
inhibitor KN-93 and the peptide inhibitor tat-CN21. These pharmacological inhibitors 
have been previously utilized in tissues that collectively express all four isoforms of 
CaMKII, resulting in inhibition of CaMKII activity (Rokolya and Singer 2000, Vest, 
O'Leary et al. 2010, Westenbrink, Ling et al. 2015). Additionally, these inhibitors target 
the regulatory region, which is highly conserved among all the known CaMKII isoforms. 
We thus assume these inhibitors will target all four isoforms of CaMKII. For our genetic 
manipulations, we chose to manipulate the δ isoform as mRNA levels of this particular 
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isoform are expressed at much higher levels in astrocytes compared to the γ isoform 
(Takeuchi, Yamamoto et al. 2000). Our data suggests alterations in CaMKII regulate 
EAAT1 mediated changes in glutamate uptake, based on a reduction in [3H]-glutamate 
uptake upon transfection with the Asp136Asn mutant of δCaMKII. A rather 
straightforward conclusion underlying this observation is that the Asp136Asn mutant 
forms homomultimers with wild-type δCaMKII, thus causing a dominant-negative effect 
and resulting in cellular functional alterations, in a manner similar to a recently described 
Lys42Met mutant of CaMKII (Kabakov and Lisman 2015). However, it is also feasible 
that the molecular mechanism underlying this finding is the generation of heteroisomeric 
multimers of CaMKII upon addition of this mutant.  In fact, co-assembly of CaMKII 
isoforms within the twelve subunit holoenzyme has been described to occur before 
(Vallano 1989, Kolb, Hudmon et al. 1998, Brocke, Chiang et al. 1999), and thus provides 
a strong rationale for this mechanism of regulation. Regardless of if and how the 
monomeric subunits combine, it is clear that a reduction in CaMKII activity results in a 
reduction in glutamate uptake.  
Furthermore, compensatory changes in CaMKII isoform expression and 
regulation can occur during pathological states, thus we cannot exclude the possibility of 
either a switch in isoform-specific regulation or dual regulation by both CaMKII isoforms 
on EAAT1 function. A recent study describes a rationale for the former mechanism, 
whereby a decrease in γCaMKII mRNA is accompanied by a concurrent increase in 
δCaMKII mRNA as a result of a lumbar spinal nerve injury (Bangaru, Meng et al. 2015). 
Additionally, alterations in the expression of specific CaMKII isoforms have been 
reported following injury or as a result of pathological conditions. In a Lysophosphatidic 
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acid (LPA) receptor knockout mouse, which mimics a schizophrenia phenotype, an 
increase in the level of βCaMKII has been reported in the knockout compared to the 
wild-type mouse (Musazzi, Di Daniel et al. 2011). This alteration in βCaMKII decreases 
the ratio between the two predominant CaMKII neuronal isoforms (α/β CaMKII), which 
has been shown to be important for neuronal maturation during development, subcellular 
localization, synaptic activity and strength (Thiagarajan, Piedras-Renteria et al. 2002, 
Fink, Bayer et al. 2003, Musazzi, Di Daniel et al. 2011). While the importance of such a 
ratio has not been elucidated for the γ and δCaMKII isoforms, one may hypothesize that 
in a manner similar to α and β CaMKII, skewing the endogenous ratio may play a role in 
altering both physiological and pathological processes.  
The protein sequences of the four human CaMKII isoforms are ~95% conserved 
in the catalytic domain, with overall conservation of the entire CaMKII sequence being 
~60%. However, major differences are found in the variable region, located within the 
hub domain, where sequence inserts can contain substrate-targeting motifs that are unique 
to each isoform. For example, it was originally thought that βCaMKII had an F-actin 
binding domain within the variable region that the other isoforms lack (Fink, Bayer et al. 
2003). Now, it appears that both δ and γCaMKII may interact with F-actin and inhibit its 
polymerization, albeit with a lower affinity (Hoffman, Farley et al. 2013). However, even 
within the βCaMKII isoform, splice variants exist that differentially target F-actin 
(Zheng, Redmond et al. 2014). Substrate-binding of the different CaMKII isoforms is a 
complex phenomenon and needs to be examined in greater detail. While the functional 
consequences have not been elucidated, it is known that astrocytes express a single splice 
variant of δCaMKII known as δ2, and two splice variants of γCaMKII γA and γB (Vallano, 
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Beaman-Hall et al. 2000). Other than affecting substrate specificity, differential domains 
in the variable region of CaMKII can also affect cellular localization that may result in 
functional discrepancies. It is thus clear that if compensatory changes in specific CaMKII 
isoforms were to occur, substrate specificity and cellular localization can be altered. 
Taken together, it is plausible that EAAT1 is a substrate for either one or both isoforms 
of CaMKII expressed in astrocytes.  
 
Isoform specificity of astrocytic glutamate transporter regulation 
In the rodent central nervous system, GLAST and GLT-1 are expressed on the 
same astrocytes (Lehre, Levy et al. 1995, Haugeto, Ullensvang et al. 1996). Where they 
differ is their level of expression based on the tissue or cell type they are studied in. For 
example, while GLAST expression is consistently described in astrocytes in the cortex 
(Lehre, Levy et al. 1995), higher expression is also reported in specialized cells such as 
the cerebellar Bergmann glia and retinal Müller cells (Torp, Danbolt et al. 1994, Rauen, 
Rothstein et al. 1996). In keeping with these findings, GLAST knockout mice exhibit 
cerebellar ataxia, the inability to perform complex tasks of coordination, and severe 
cerebellar edema in response to an ischemic insult (Watase, Hashimoto et al. 1998). 
GLAST knockout mice also display increased retinal damage as a result of ischemia, and 
altered electroretinograms and oscillatory potentials compared to wild-type mice (Harada, 
Harada et al. 1998). Furthermore, chronic utilization of GLAST antisense 
oligonucleotides results in neuronal excitotoxicity in motor neurons and striatal neurons, 
elevated extracellular glutamate and progressive paralysis in vivo in a rodent model 
(Rothstein, Dykes-Hoberg et al. 1996), suggesting that aberrations in EAAT1 activity 
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result in phenotypes throughout the brain due to their ubiquitous expression. Our model 
suggests a loss of CaMKII signaling decreases glutamate uptake via EAAT1, eventually 
leading to dysregulated glutamate uptake and neuronal death. Based on the cellular and 
tissue distribution of the EAAT1 transporter, it is plausible that a loss of CaMKII 
signaling will result in cortical deficits, and a particularly severe phenotype in regions 
like the cerebellum and retina, where glutamate uptake is largely governed by EAAT1. 
Recent work from the Amara laboratory shows that CaMKII phosphorylation of a 
PDZ scaffolding protein, Discs large homolog 1 (DLG1/SAP97), decreases surface 
expression of a splice variant of EAAT2 known as EAAT2b and presumably transporter 
activity (Underhill, Wheeler et al. 2015). This effect was isoform specific as EAAT2a 
trafficking was not affected by CaMKII signaling. Our study confirms that EAAT2a is 
not altered by CaMKII signaling, and extends this work by showing that CaMKII can 
produce isoform specific modulation of EAAT activity. We did not test the regulation of 
EAAT2b by CaMKII, although the DLG1/SAP97 protein is endogenously expressed by 
HEK293T cells (Cai, Li et al. 2008). While Underhill et al. favor an indirect mechanism 
of regulation based on membrane stability of EAAT2b by a phosphorylated scaffolding 
protein, we think phosphorylation of the transporter itself is an additional key regulatory 
mechanism conferred by CaMKII. Interestingly, Thr37 is not conserved in EAAT2 
(Figure 2), providing a basis for the lack of a CaMKII regulatory effect on EAAT2 
observed in the experiments described in this study. Remarkably, Thr37 is conserved in 
only one other glutamate transporter- EAAT4. It is noteworthy to point out that EAAT1 
and EAAT4 represent the entirety of glutamate transporter expression in the cerebellum, 
strengthening the notion that a loss of CaMKII signaling would be highly detrimental in 
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the cerebellar region. In fact, a βCaMKII knockout mouse exhibits cerebellar ataxia 
(Bachstetter, Webster et al. 2014), a phenotype identical to that observed in the GLAST 
knockout mouse (Watase, Hashimoto et al. 1998) which may be due to convergent 
molecular mechanisms. Future studies are needed to determine whether EAAT4, 
expressed almost exclusively in the cerebellum (Fairman, Vandenberg et al. 1995), is 
directly phosphorylated by CaMKII, and what the functional consequence of this post-
translational modification may be.  
The idea that a kinase can differentially regulate subtypes of transporters is not 
unprecedented. For example, glycogen synthase kinase 3β has been shown to 
differentially modulate GLAST and GLT-1, producing a down-regulation in GLAST but 
up-regulation in GLT-1 activity and cell-surface expression via phosphorylation of the 
transporters (Jimenez, Nunez et al. 2014). Collectively, glutamate transporter regulation 
by CaMKII appears complex in that it can have opposing outcomes on transporter 
function that are isoform dependent.  Additional studies are required to determine how 
EAAT1 activity is regulated by CaMKII (i.e. gating or trafficking), in what manner basal 
regulation of EAAT1 by CaMKII is coupled to EAAT2b function, and whether specific 
states of CaMKII activation may be important for this isoform specific regulation.  
 
CaMKII autophosphorylation mutants do not alter glutamate uptake 
Canonical CaMKII autophosphorylation occurs when Ca2+-bound CaM displaces 
the autoregulatory domain from the catalytic cleft of CaMKII, allowing an intrasubunit 
autophosphorylation reaction directed at the Thr286/287 residue in the autoregulatory 
domain to occur. CaMKII phosphorylation at this site renders the kinase autonomously 
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active independent of Ca2+/ CaM, allowing CaMKII to phosphorylate substrates more 
efficiently (Lai, Nairn et al. 1987, Miller, Patton et al. 1988). While the majority of this 
dissertation pertains to astrocytic CaMKII, much of our current understanding of this 
enzyme comes from its role in neurons. For example, autophosphorylation at Thr286/287 
on CaMKII was thought to be an essential event for its translocation to the PSD (Strack, 
Choi et al. 1997, Strack and Colbran 1998), a specialized area within the dendritic region 
of neurons that is packed with a large number of proteins, and contains over 30 CaMKII 
substrates (Yoshimura, Aoi et al. 2000, Yoshimura, Shinkawa et al. 2002). Once recruited 
to the PSD, these substrates become easily accessible to CaMKII and are increasingly 
phosphorylated. However, it now appears that autophosphorylation of CaMKII may not 
be necessary for its translocation, but it instead alters dwell time of the kinase at the PSD 
(Shen, Teruel et al. 2000). Thus, even in a cellular context where CaMKII has been 
studied in great detail, it is clear that the functional consequences related to CaMKII 
autonomy are rather complex and not fully understood. What is clear is that autonomous 
CaMKII serves as a form of molecular memory that is important for the kinase to retain 
past cellular activity even when calcium levels return to baseline.  
Less is known about functional events associated with CaMKII 
autophosphorylation in the astrocyte or HEK293T cells in comparison to a neuron. 
Interestingly, the percentage of autonomous CaMKII activity in an astrocyte is one of the 
highest described for any cell type ranging from ~24-75% (Song, Bellail et al. 2006, 
Ashpole, Chawla et al. 2013), suggesting that astrocytic CaMKII may not need external 
provocation to activate calcium signaling machinery in order to activate downstream 
signaling mechanisms. CaMKII autophosphorylation mutants (Thr287Asp or Thr287Val 
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represented in Figure 10) did not result in altered [3H]-glutamate uptake. Our data 
suggests that CaMKII regulation of [3H]-glutamate uptake has a maximal effect with 
autonomous cellular kinase. This idea is supported by the inhibition of CaMKII reducing 
EAAT1 mediated glutamate uptake (Figures 8-10), but a lack of increased EAAT1 
mediated glutamate uptake upon addition of a calcium ionophore ionomycin (Figure 12). 
It is unsurprising that Thr287Asp, a CaMKII mutant that increases autonomous activity, 
did not produce an increase in [3H]-glutamate uptake if calcium mobilization does not 
appear to be instrumental in regulating glutamate uptake (Figure 10). However, upon 
experimental confirmation that Thr287Val produced a reduction in CaMKII autonomous 
activity as a measure of AC-2 phosphorylation, a lack of effect in [3H]-glutamate uptake 
via EAAT1 was unexpected. This could be due to a number of reasons. The pool of 
CaMKII accessible for [γ-32]P measurements versus regulating glutamate uptake may be 
different, for example the total CaMKII measurements we make pertain to all four 
isoforms whereas the regulatory effect observed is due to just one isoform. In keeping 
with this idea, differential changes in CaMKII isoforms have been reported as a result of 
pathological changes. Second, a portion of the regulatory effect of CaMKII on EAAT1 
occurs independent of phosphorylation at Thr37. It is also possible that even with a small 
percentage of autonomous activity, downstream cellular signaling mechanisms may be 
adequate to result in alterations in EAAT1-mediated glutamate uptake. These 
explanations may thus explain a lack of regulatory effect by CaMKII 
autophosphorylation mutants on EAAT1-mediated glutamate uptake.  
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Linking our findings to astrocytic CaMKII signaling 
Calcium signaling in astrocytes is important for sensing and integrating activity at the 
synapse and releasing gliotransmitters, among a number of functions (Halassa, Fellin et 
al. 2007). Based on reports from our laboratory and others, CaMKII appears to 
homeostatically regulate functions in the astrocyte such as glutamate uptake, release of 
the gliotransmitter ATP, maintaining a static phenotype/preventing migration from 
occurring, and maintaining calcium flux between cells. Thus, autonomous levels of 
astrocytic CaMKII appear to be integral to maintaining cell survival and function.  
Our laboratory has previously characterized disruptions in astrocytic function 
associated with CaMKII inhibition. The application of pharmacological CaMKII inhibitor 
tat-CN21 to cortical astrocyte cultures resulted in the induction of calcium oscillations 
and mitochondrial membrane depolarization (Ashpole, Chawla et al. 2013). Additionally, 
an increase in extracellular ATP due to aberrant release of the gliotransmitter was 
detected as a consequence of CaMKII inhibition, and this finding was linked to calcium 
influx via the N-type calcium channels (Cav2.2). ATP is one of the most abundant 
gliotransmitters within cortical astrocytes (Coco, Calegari et al. 2003), and the release of 
ATP through purinergic receptors located on both neurons and astrocytes facilitates 
communication of ATP with neurons, microglia, and capillaries (Inoue, Koizumi et al. 
2007). Interestingly, the release of astrocytic ATP has been shown to decrease neuronal 
excitability in the retina (Newman 2003) as well as decrease spontaneous neuronal 
calcium oscillations (Koizumi, Fujishita et al. 2003) and hippocampal excitatory post-
synaptic currents (Zhang, Wang et al. 2003). These findings and other reports suggest 
ATP released by astrocytes plays an inhibitory role, thereby suppressing synaptic 
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transmission (Pascual, Casper et al. 2005). On the other hand, glutamate released by 
astrocytes has been shown to activate neurons via excitatory pathways. Thus, the 
interplay between the release of two key gliotransmitters from astrocytes, ATP and 
glutamate, appears to have opposing functions. We were surprised to find that the 
concentration of extracellular glutamate was not altered upon pharmacological inhibition 
of CaMKII in our studies. These findings suggest that the phenotype associated with ATP 
release may occur temporally before a phenotype associated with glutamate release 
cancels it out (inhibition vs excitation). It may thus be likely that neuronal synaptic 
function can initially be suppressed if ATP was the only gliotransmitter at play prior to 
excitotoxicity induced by the buildup of excess extracellular glutamate.  
Conversely, reports also suggest that CaMKII activation in an astrocyte may be 
associated with detrimental outcomes. For example, increased phosphorylation of Cx43, 
a gap junction found on the astrocyte membranes, has been shown to result in a decrease 
in the open channel probability and diminished calcium flux between cells (Dermietzel, 
Traub et al. 1989, Huang, Laing et al. 2011, Xu, Kopp et al. 2012). These findings 
suggest limited intercellular communication between cells upon CaMKII activation in 
which calcium is a very important second messenger. Increased CaMKII signaling may 
also hyperphosphorylate vimentin, a cytoskeletal protein that has been implicated in 
decreased migration when phosphorylated. Interestingly, this regulation appears to occur 
in a manner different from the positive regulation of CaMKII on the ClC-3 channels 
which results in an increased migratory phenotype.  
While alterations in phenotypes associated with calcium signaling do not always 
seem to occur in the same direction, it is clear that both increases and decreases in 
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CaMKII, a key enzyme regulated by calcium, can be detrimental to cellular function in 
astrocytes. In fact, an understanding of the functional role of CaMKII in astrocytes is 
only just starting to be achieved. In total, alterations in a multifunctional kinase that is 
known to regulate ion channels, scaffolding proteins, glutamate uptake, gliotransmitter 
release and cell-to-cell communication may likely result in global changes in the brain 
that can ultimately affect cell survival.  
 
Implications towards neurodegenerative diseases 
Studies utilizing both genetic and pharmacological tools to inhibit astrocytic and 
neuronal CaMKII results in a phenotype of disrupted calcium homeostasis, increased 
cellular excitability, aberrant glutamatergic signaling, and loss of neurons (Carter, Haider 
et al. 2006, Ashpole and Hudmon 2011, Ashpole, Song et al. 2012, Klug, Mathur et al. 
2012, Ashpole, Chawla et al. 2013). It is thus unsurprising that dysregulated CaMKII 
activity has been implicated in neurodegenerative conditions such as Alzheimer’s disease 
(Min, Guo et al. 2013). During conditions of ischemia, CaMKII has been shown to 
initially activate, followed by rapid inactivation of the kinase for a prolonged period of 
time (Aronowski, Grotta et al. 1992). In particular, the degree of CaMKII inactivation has 
been shown to correlate with the severity of neuronal death, suggesting that a loss of 
CaMKII signaling is associated with neuronal death in animal models (Hanson, Grotta et 
al. 1994, Waxham, Grotta et al. 1996, Coultrap, Vest et al. 2011).  
In fact, alterations in glutamatergic neurotransmission, and in particular glutamate 
uptake, are observed in a number of neurodegenerative diseases such as traumatic brain 
injury, amyotrophic lateral sclerosis, Alzheimer’s disease, and ischemia. In particular, 
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reduced GLAST and GLT-1 protein expression has been observed following a controlled 
cortical impact injury in the rodent hippocampus, accompanied by a decreased in 
radiolabeled D-Asp (Rao, Baskaya et al. 1998). Additionally, alterations in glutamatergic 
neurotransmission have been reported in at least two murine models of Alzheimer’s 
disease, concomitant with a decrease in GLAST and GLT-1 expression (Schallier, 
Smolders et al. 2011, Cassano, Serviddio et al. 2012). Synthesizing these findings from 
the literature, it appears that a loss of CaMKII signaling and aberrant glutamate uptake 
have a similar phenotype, ultimately resulting in calcium dysregulation and neuronal 
death in the brain. Based on our findings in conjunction with the Underhill study 
(Underhill, Wheeler et al. 2015), it appears that reduced CaMKII signaling would lead to 
a decrease in EAAT1-mediated glutamate uptake, unaltered EAAT2a-mediated glutamate 
uptake, and increased EAAT2b-mediated glutamate uptake. A possibility underlying the 
differential CaMKII regulation of these glutamate transporters is to maintain a balance in 
the levels of astrocytic glutamate uptake during physiological and pathological 
conditions. Whether CaMKII regulation the glutamate transporters is one that is transient, 
with the transporters rapidly (within minutes) inserting in and out of the membrane, or a 
result of a longer-lasting phenotype remains to be seen.  
In sum, our findings suggest CaMKII regulates glutamate uptake via EAAT1. 
This regulation may provide the basis for a phenotype involving excess extracellular 
glutamate, aberrant glutamate receptor activation and neuronal death that ensues as a 
result of a loss of CaMKII signaling in neurodegenerative conditions.  
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Future Directions 
Our studies implicated phosphorylation of the Thr37 residue on EAAT1 as 
instrumental in CaMKII regulation of EAAT1-mediated glutamate uptake. We initially 
uncovered this finding by detecting significant [γ-32]P incorporation of the EAAT1 N-
terminus in SPOTS blot tiling assays of the intracellular portions and GST-fusion 
proteins of the N- and C- termini of EAAT1 and EAAT2. We then honed in on the actual 
residue using Ala mutants in both the SPOTS blot assays and GST-fusion proteins, and 
measured alterations in functional glutamate uptake in a transfected HEK293T cell line. 
However, these assays do not definitively test CaMKII directly phosphorylates the 
EAAT1 protein at Thr37. Thus, we tried to perform mass spectroscopy, an analytical 
technique that ionizes peptides in a protein, and then sorts the ions based on their mass to 
charge ratio.  Using a co-immunoprecipitation strategy, we transfected HEK cells with 3x 
FLAG-tagged EAAT1 and performed a pull down assay using a FLAG or IgG antibody. 
We detect significant pulldown using a FLAG antibody from transfected 3x FLAG-
tagged EAAT1 lysate (representative image shown in Figure 12) and minimal 
pulldown for the same conditions using an IgG antibody with a Western blot. No 
detectable protein was pulled down in the untransfected HEK cell lysate, with either the 
FLAG or IgG antibodies, suggesting that we were able to detect isolation of the FLAG-
tagged EAAT1 using a Western strategy. However, using either Coommasie Stain or 
Silver stain, we were not able to detect an appreciable difference between the FLAG and 
IgG pulldown conditions, for either the transfected or untransfected lysate. Thus, we are 
continuing to optimize this technique in order to detect enough protein to perform mass 
spectroscopy on our samples. For the purposes of this dissertation, we were not able to 
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obtain a mass spectroscopic readout of CaMKII phosphorylation sites on the EAAT1 
protein. 
In addition to the use of a heterologous expression system such as HEK293Ts and 
glioma cells, we wanted to confirm our findings in mammalian astrocytes. For this 
purpose, we obtained human embryonic astrocytes (hEATs), an hTERT immortalized 
fetal astrocyte cell line.  Unfortunately, we did not obtain this cell line till very recently 
and thus were not able to replicate the majority of our findings in it. In order to 
characterize the hEAT cell line, we performed immunocytochemistry to first test the 
purity and protein expression of the cell line. Our immunocytochemical findings suggest 
that hEATs are GFAP positive, a protein marker for astrocytes (Figure 19A). Markers 
for neurons (MAP2), microglia (OX-42) and oligodendrocytes (Olig-2) respectively were 
not detected in culture (Figure 19B-D), suggesting the lineage of this cell line is similar 
to that of differentiated astrocytes. We next tested the ability of hEATs to uptake 
glutamate to determine if they served as a useful model system. We found that [3H]-
glutamate counts were relatively low for naïve hEATs (compared to counts normalized to 
protein concentration in rodent cultured cortical astrocytes, HEK293Ts, and A172s), with 
no significant reduction elicited by the addition of the inhibitor 100µM TBOA (Figure 
19E) suggesting this cell line does not uptake glutamate via the glutamate transporters. 
However, transient transfection of hEATs with EAAT1 and EAAT2 increased [3H]-
glutamate uptake by 10-12 fold, substantially greater compared to HEK293Ts. EAAT1 
and EAAT2-mediated glutamate uptake were reduced by their respective inhibitors, 
UCPH-101 and TBOA. These data suggest fetal astrocytes may represent a heterologous 
expression system closer to native astrocytes to examine glutamate uptake in.  
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Figure 19: Characterization of human embryonic fetal astrocytes (hEATs). In A-D, shown 
are representative images of a field of astrocytes immunostained with DAPI (blue) and A: GFAP 
(green), B: MAP2 (green), C: OX42 (green), and D: Olig-2 (red). The scale bar represents 100 
µM length. E: Average [3H]-glutamate uptake in EAAT1 and EAAT2 transfected cells (n=3, ± 
S.D) normalized to untransfected hEAT cells. Inhibitors 10 µM UCPH-101 and 100 µM TBOA 
were added to EAAT1 and EAAT2 transfected cells respectively for 20 minutes prior to a 20 
minute [3H]-glutamate uptake measurement protocol. 
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CONCLUSIONS 
The findings of this dissertation expand our understanding of the role of astrocytic 
CaMKII in the regulation of a key function, glutamate clearance via the EAAT proteins. 
In particular, our data identifies EAAT1 as a novel CaMKII substrate and implicates the 
Thr37 residue in EAAT1 as a key phosphorylation site for CaMKII that is linked to 
EAAT1-mediated glutamate uptake. A pathological loss of CaMKII signaling and 
dysregulated calcium homeostasis in astrocytes can thus diminish glutamate uptake, 
which may contribute to neurotoxic effects due to increased extracellular glutamate and 
aberrant activation of glutamate receptors.  
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